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Insulin-like growth factor 1 (IGF1) plays an important role in breast cancer initiation and 
progression due to its regulation of cell proliferation, migration, and invasion. Our laboratory 
previously demonstrated that overexpression of constitutively activated IGF1 receptor (IGF1R) 
transformed human mammary epithelial cells and induced epithelial to mesenchymal transition. 
These characteristics make IGF1R an attractive therapeutic target, however, only subsets of 
patients have shown beneficial response to anti-IGF1R therapy in clinical trials, likely due to 
crosstalk with the insulin signaling pathway and lack of predictive biomarkers. To identify 
biomarkers of response to activated IGF1 and insulin signaling, we performed a proteomic 
screen in 21 breast cancer cell lines stimulated with IGF1 and insulin. We identified E-cadherin 
(CDH1), a major component of the adherens junction, as a repressor of IGF1 and insulin 
signaling. We further provide evidence that loss of E-cadherin hyperactivates the IGF1R 
pathway and increases sensitivity to IGF1R targeted therapy, thus highlighting the IGF1R 
pathway as a potential target in E-cadherin deficient breast cancer. Knockdown or antibody-
mediated inhibition of E-cadherin increased IGF1-induced activation of IGF1R signaling and 
cell cycle progression. IGF1R and E-cadherin co-localized at points of cell-cell contact and a 
direct endogenous interaction using in situ proximity ligation assay indicated a physical 
regulation of E-cadherin on IGF1R signaling. Importantly, the E-cadherin gene (CDH1) is 
genetically lost in invasive lobular breast carcinoma (ILC), a subtype of breast cancer accounting 
for ~10-15% of total cases. We found increased expression of IGF1 ligand and levels of IGF1R 
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phosphorylation in E-cadherin deficient estrogen receptor positive (ER+) ILC in TCGA 
compared to ER+ invasive ductal carcinomas (IDC).  We demonstrated that IGF1R and 
PI3K/Akt pathway inhibitors were effective in inhibiting growth in ER+ ILC cell lines and 
synergized with endocrine therapy. Additionally, we showed efficacy of IGF1R inhibition in ILC 
xenografts cultured ex vivo. Our data supports the use of IGF1R pathway inhibition as a potential 
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1.0  INTRODUCTION 
1.1 BREAST CANCER 
Breast cancer is the second most common malignancy in women in the United States, behind 
cutaneous melanoma, accounting for an estimated 246,000 new diagnoses and over 40,000 
deaths per year1. The incidence of breast cancer has increased over the last four decades, likely 
due to enhanced detection methodology, heightened awareness of the importance of regular 
screening, and trends in female parity that alter inherent risk for breast cancer development1,2. 
Despite the high incidence of breast cancer, survival outcomes are remarkable, with five-year 
overall survival hovering around 90%. However, the five-year survival rate for patients with 
advanced metastatic disease has remained stagnant at approximately 25%, highlighting the 
importance of understanding the biology underlying metastatic disease and developing new 
therapeutic targets1,3,4. 
1.1.1 Molecular subtypes of breast cancer 
Breast cancer is stratified into distinct molecular and histological subtypes, which serve to guide 
treatment strategy and guidelines. Tumors are classified by expression of estrogen receptor (ER), 
progesterone receptor (PR), and epidermal growth factor-2 receptor (Her2). ER-positive disease 
is primarily treated with endocrine therapy to block estrogen signaling, including selective 
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estrogen receptor modulators (e.g. tamoxifen, raloxifene [SERM]) that compete with estrogen for 
binding to ER, selective estrogen receptor downregulators (e.g. fulvestrant/ICI [SERD]) that bind 
and induce degradation of ER, and aromatase inhibitors (e.g. exemestane) that block the 
conversion of androgens to estrogen in postmenopausal women5,6. Similarly, Her2-positive 
tumors are treated with targeted therapy to inhibit Her2-mediated signaling, including antibody 
biologics (e.g. trastuzumab, pertuzumab, TDM-1) and receptor tyrosine kinase inhibitors (e.g. 
Neratinib)7–9. Both types of treatment modalities are typically used in ER- and Her2-positive 
tumors. Tumors that lack expression of all three receptors, and regarded as the most aggressive, 
are referred to as the triple negative breast cancer (TNBC) subtype10. Unfortunately, there are 
less therapeutic options for patients with TNBC, and patients mainly receive chemotherapy as 
standard of care. Recent advances in TNBC treatment have been made, including the FDA 
approval of PARP inhibitor (e.g. Olaparib) for the treatment of advanced disease harboring 
BRCA1/2 mutations, and the initiation of clinical trials investigating the use of 
immunotherapy10–13. Further research is required to identify targeted therapy for this subtype of 
the disease.  
In addition to receptor expression, breast tumors are molecularly classified based on their 
gene expression profiles. Not surprisingly, unsupervised hierarchical clustering segregated ER-
positive from ER-negative tumors, but additionally identified five unappreciated intrinsic 
subtypes (LumA, LumB, Her2, Basal, Normal-like). These subtypes are routinely determined 
using gene expression from a concise 50-gene set known as PAM50. Because of the prognostic 
significance associated with each PAM50 subtype, clinical versions of the panel (e.g. Prosigna, 
MammaPrint, Oncotype DX) are now used to identify risk for distant recurrence and aid in 
treatment decisions, mainly whether a patient would gain potential benefit from chemotherapy.  
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1.1.2 Histological subtypes of breast cancer 
Breast cancer is divided into two major histological subtypes. Invasive ductal carcinoma (IDC) is 
the most common subtype, accounting for 70% of total breast cancer cases diagnosed per year. 
This subtype grows as the typical mass in the breast, usually identified by mammography or self-
breast exam. In contrast, invasive lobular carcinoma (ILC) accounts for 10-15% of total cases, 
approximately 30,000 cases per year in the United States14,15. This subtype of disease is 
molecularly defined by the loss of functional E-cadherin (CDH1), a major component of the 
adherens junction, leading to a discohesive linear growth pattern throughout the breast tissue 
(Figure 1)14,16,17. ILC tumors are often clinically diagnosed using an E-cadherin/p120 dual 
immunohistochemistry stain—IDC tumors display brown membranous E-cadherin staining 
whereas ILC tumors display a lack of brown membranous E-cadherin staining coupled with pink 




Figure 1: Ductal and lobular carcinoma: the major histological subtypes of breast cancer. 
          H&E and E-cadherin/p120 staining depicted for both subtypes of disease. 
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Due to the distinct growth pattern, ILC is often diagnosed late compared to IDC because the 
difficulty in detection14,17,19. Ciriello and colleagues recently described the genomic landscape of 
127 ILC tumors in The Cancer Genome Atlas (TCGA) as compared to IDC tumors15. Similar to 
previous reports, they showed that the loss of E-cadherin protein occurs in 90% of ILC, and is 
generally due to truncating mutations, loss of heterozygosity, or transcriptional repression14–17. In 
addition to E-cadherin alterations, they found 71% of ILC tumors harbor alterations in either 
PIK3CA (hotspot/missense mutations) or PTEN (truncating/missense mutation or high level copy 
number loss), likely leading to the high Akt activity they identified as compared to IDC15,20,21. 
ER status is also significantly different between IDC and ILC; ILC tumors are 90% ER-positive 
compared to 60-70% in IDC14,15,17. Due to this, ILC patients are treated with endocrine therapy 
to target ER signaling, but interestingly, data from the BIG 1-98 trials suggest that ILC tumors 
display resistance to traditional endocrine therapy (tamoxifen) compared to IDC22. In addition, 
results from numerous clinical studies indicate that ILC patients exhibit more frequent late 
recurrences associated with poorer prognosis compared to IDC, despite good prognostic markers 
(e.g. low Ki67 expression, high ER expression)14,19,23,24. This highlights the need to understand 
the mechanism underlying endocrine resistance and improve therapeutic options in ILC patients 
based on specifically activated mitogenic pathways. 
1.2 INSULIN-LIKE GROWTH FACTOR AND INSULIN SIGNALING 
The insulin-like growth factor (IGF) and insulin systems consist of three ligands (IGF1, IGF2, 
and insulin), two insulin receptor substrate proteins (IRS1/2), six IGF binding proteins (IGFBP1-
6), and five receptors (insulin-like growth factor 1 receptor [IGF1R], insulin-like growth factor 2 
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receptor [IGF2R], insulin receptor-A and B [InsR-A and InsR-B], and IGF1/insulin hybrid 
receptor [HybR])25–28. Activation of this pathway by ligand binding plays a crucial role in normal 
mammary gland development and physiology and in the transition to neoplastic lesions29. 
Endocrine IGF1 ligand is produced in the liver and is released in response to growth hormone 
(GH) secreted by the pituitary, however autocrine and paracrine IGF1 signaling also occur30,31. 
IGF1R and InsR are both tetrameric proteins composed of two extracellular α-subunits 
that bind ligand, covalently linked to two intracellular β-subunits, which contain the tyrosine 
kinase signaling domains32–34. Interestingly, although IGF1R and InsR are encoded on different 
chromosomes with different numbers of exons, the receptors share high amino acid sequence and 
structural homology35,36. The ligand binding domains (α-subunit) share 55% amino acid 
similarity, and the tyrosine kinase domains (β-subunit) share 72% homology with 100% 
homology found in the ATP-binding domains25,37. The binding of ligand to IGF1R and InsR 
leads to conformational changes in structure and transphosphorylation of the receptor, which 
triggers the activation of two main intracellular signaling cascades: the phosphatidylinositol 3-
kinase/Akt kinase (PI3K/Akt) pathway and the Raf kinase/mitogen activated protein kinase 
(Raf/ERK) pathway (Figure 2)28. Although IGF1R and InsR share common downstream 
pathways, their biological roles are not completely identical: IGF1R mainly mediates 
proliferation, migration, cellular transformation, and anti-apoptotic events, whereas InsR mainly 
controls the metabolism of glucose38. Nevertheless, there is extensive crosstalk between IGF1R 
and InsR; IGF1 can bind InsR and insulin can bind IGF1R, albeit with a lower affinity compared 
to their primary targeted receptors25,39–41. Additionally, HybRs consisting of one α/β subunit of 
IGF1R and one α/β subunit of InsR have been reported, and potentially exceed IGF1R content in 
breast tumors by greater than 75%42–45. Studies evaluating activity of HybR have shown that they 
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respond with much greater potency to IGF1 than insulin, and have different ligand binding 
affinity compared to non-hybrid (holo) receptors46–49. However, as most cells express a 
combination of IGF1R, InsR and HybR, and few methods exist to specifically examine activated 
HybR in living cells, ascribing HybR specific effects has been difficult50,51. We recently 
published a methodology to examine specific signaling and phenotypic effects due to activation 
of holo-IGF1R and holo-InsR compared to HybR51. Similar to previously published data, we 
demonstrated that HybR activation functions more closely to IGF1R than to InsR in promoting 
mitogenic signaling and proliferation, whereas InsR mainly regulated glucose uptake25,51.  
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Figure 2: IGF1R signaling overview. 
IGF1/2 ligand bind to IGF1R and initiates an intracellular signaling cascade mediated mainly through 
PI3K/Akt and Raf/MEK/ERK signaling leading to proliferation, growth, and survival. A similar signaling 
cascade is observed for insulin signaling via InsR. Figure was generated by modifying an existing template 
from ProteinLounge (access via University of Pittsburgh HSLS Library). 
Inhibition of phenotype 
Activation of phenotype 
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1.2.1 IGF1 signaling and mammary gland development  
Proper GH-IGF1 signaling is required for normal mammary gland development52. In addition to 
endocrine IGF1 produced in the liver, IGF1 is secreted from the fibroblast and immune 
components within stroma of the mammary gland in a paracrine manner53–55. Paracrine IGF1 
signaling is thought to be more potent than endocrine signaling (and bypasses the requirement 
for GH action) and initiate terminal end bud (TEB) growth and ductal branching within the 
mammary fat pad54,56. Supporting this, IGF1 null (-/-) female mice display decreased mammary 
gland development that can be rescued with continuous injections of IGF154. Combined IGF1 
and estradiol injections further increased TEB formation and ductal growth indicating that 
estrogen signaling synergizes with IGF1 to enhance this process54,57,58. Additionally, it has been 
demonstrated that IGF1 rescues the impaired ductal development in GH-deficient mammary 
glands, but that GH is unable to rescue development in IGF1-null glands, further supporting the 
notion that IGF1 is the critical mediator acting downstream of GH action59. 
In addition to mammary gland development, IGF1-IGF1R signaling is required for proper 
mammary gland morphogenesis. This was demonstrated through mammary gland transplantation 
assays using IGF1R-deficient embryonic mammary buds transplanted into cleared mammary fat 
pads of wild-type mice. These buds exhibited decreased cellular proliferation and growth 
potential compared to wild-type buds during mammary gland morphogenesis, highlighting the 
importance of epithelial IGF1R expression in the mammary gland54,60. The loss of IGF1-IGF1R 
mediated mammary gland morphogenesis is suggested to be a result of diminished cell cycle 
progression and elevated apoptosis in the gland61–63. However, although data implicates IGF1 as 
a potent mediator of mammary gland development, coordination with additional growth factors 
such as epidermal growth factor (EGF) and transforming growth factor-β (TBFβ), and other 
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IGF1 pathway components such as IGF1R and IGFBPs is necessary for maximal mammary 
gland signaling and full development to a mature gland64,65. 
1.2.2 Deregulation of IGF1R signaling in breast cancer  
Similar to other growth factor signaling pathways, the GH-IGF1 axis is known to be deregulated 
in the progression from normal mammary gland to cancer33,34,52. The earliest epidemiological 
evidence was reported in a population of patients with primary GH insensitivity, a disease 
termed Laron syndrome in 1966. Laron syndrome is associated with congenital IGF1 
deficiencies driven by a genetic alteration(s) in GHR affecting expression and activity. 
Individuals with this syndrome suffer from dwarfism and high rates of obesity, associated with 
high levels of GH and low levels of serum IGF166,67. Strikingly, these individuals are inherently 
protected from cancer development compared to non-Laron wild-type relatives, suggesting the 
importance of this pathway in cancer development68. This finding was supported using an in vivo 
laboratory model of Laron syndrome – which lacks GHR/GH binding protein69. When crossed 
with transgenic models of mammary and prostate cancer, mice with this genotype displayed 
reduced incidence of tumor development compared to wild-type littermates70,71. Conversely, high 
levels of circulating IGF1 and IGF2 have been shown to elevate risk for cancer development, 
including breast, colon, and prostate cancer72–77. Supporting this, transgenic mice overexpressing 
IGF1 driven on the myoepithelial K5 promoter (BK5.IGF1) develop spontaneous mammary 
gland and skin tumors that are driven by paracrine IGF1 signaling78–80.  
 Elevated IGF1-IGF1R activity in the mammary gland is thought to promote cell 
proliferation, survival, and epithelial to mesenchymal transition leading to breast cancer 
initiation and progression. Constitutively activated IGF1R (CD8-IGF1R) has been shown to 
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transform normal mammary epithelial cells (MCF10A) by promoting increased proliferation, 
decreased apoptosis and loss of polarity in vitro, and inducing tumor growth in vivo in 
immunocompromised mice. Strikingly, overexpression of other oncogenes such as ErbB2 
(Her2), activated Ras, and cyclin D1 also disrupted acini formation and transformed mammary 
epithelial cells in vitro, but were not sufficient to induce tumor formation in vivo, emphasizing 
the importance of IGF1R81,82. Additionally, constitutively activated IGF1R has been shown to 
initiate epithelial to mesenchymal transition through activation of NFkB and induction of the 
transcription factor, Snail, leading to the downregulation of E-cadherin81,83. This, in combination 
with IGF1R crosstalk with integrins is known to mediate migratory and invasive 
phenotypes81,84,85. Data from our lab and others suggest a role for IGF1/2 signaling and efficacy 
of IGF1R/InsR inhibition in ER-negative (particularly triple negative [TNBC]) breast tumors and 
cancer stem-like cells that display EMT properties (e.g. low E-cadherin expression)52,55,86,87.  
In contrast to overexpression, inhibition of IGF1R using a tyrosine kinase inhibitor 
(BMS-536924) reversed transformation of CD8-IGF1R-MCF10A cells resulting in a reversion to 
normal acini formation, and inhibition of proliferation in multiple breast cancer cell lines88. In 
addition, IGF1R activity has been shown to promote survival to annoikis-induced apoptosis 
through activation of PI3K/Akt89. Comparable IGF1R-mediated mitogenic effects have been 
observed in the mammary gland in vivo. Transgenic female mice expressing CD8-IGF1R in the 
mammary gland demonstrated aberrant mammary gland development and palpable mammary 
gland tumor formation by 8 weeks of age90. Similarly, mammary glands from transgenic 
MMTV-IGF1R mice showed impaired ductal elongation within 55 days and palpable mammary 
tumor formation by 8 weeks of age. These phenotypes were associated with Akt, ERK, and 
STAT3 signaling activated downstream of IGF1R91.  Conversely, inhibition of IGF1R in an 
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orthotopic xenograft using a C-terminal truncated (dominant negative) IGF1R lacking the 
receptor signaling domain was shown to inhibit migration and invasion of cancer cells and 
prevent the formation of lung metastasis in vivo92. 
1.2.3 Crosstalk between IGF1R and ER signaling  
Many of the pro-tumorigenic effects of IGF1-IGF1R signaling in breast cancer may largely be 
due to the extensive crosstalk with the estrogen receptor (ER) signaling pathway, as 
demonstrated by the synergy between IGF1 and estrogen to promote proliferation35,93. This is 
likely due to the ability of IGF1 stimulation to promote phosphorylation and activation of ERα 
(S167). Becker and colleagues demonstrated that inhibition of the mTOR/S6K1 axis blocks 
IGF1-induced ERα (S167) phosphorylation and gene transcription without affecting ligand 
dependent ERα signaling, and additionally observed that site directed mutation of ERα (S167) 
reduces IGF1-mediated colony formation94. Similarly, estrogen induces an elevation in IGF1R 
and IRS1/2 expression, leading to enhanced IGF1-IGF1R signaling capacity35,93. In addition to 
estrogen-regulation of IRS1 expression, association between IRS1 and ERα in pre-pubertal 
mammary glands from BK5.IGF1 transgenic mice preferentially activated the PI3K/Akt pathway 
compared to the Ras/MAPK pathway. The authors demonstrated a switch in signaling to the 
Ras/MAPK pathway in post-pubertal mammary glands with decreased ERα expression, 
preventing the complex formation with IRS1. This highlights the crosstalk between IGF1 and 
ERα signaling in the mammary gland and may be especially relevant in women during times for 
high ERα expression in the breast, such as the pre-pubertal and post-menopausal stages of 
development80. Interestingly, tamoxifen therapy is known to decrease levels of circulating IGF1 
and expression of estrogen-regulated IGF1R pathway components, providing evidence to the 
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notion that enhanced IGF1R activity may act as a driver or occur as a result of tamoxifen 
resistance95. In support, high IGF1R and IRS1 expression have been identified as predictors of 
early ER-positive breast cancer recurrence, and indicate a role for IGF1-IGF1R signaling 
molecules in estrogen-mediated and resistant disease progression35,89,93.  
 Recently, the identification of ESR1 mutations in breast cancer as a mechanism to 
endocrine therapy resistance has rejuvenated the importance of the IGF1R pathway in breast 
cancer.  Gelsomino et al. demonstrated that mutations in the ligand binding domain of ESR1 
promote resistance to tamoxifen partially due to activation of the IGF1R signaling pathway96. 
Similarly, we have observed (Li et al.) hyperactivity of IGF1R signaling in ESR1 mutant cells 
resulting in elevation of IGF1 regulated gene transcripts97. Additionally, we observed enhanced 
IGF1 signaling capacity via PI3K/Akt activation of mutant cells that was mediated by the 
increased IRS1 expression. Both studies demonstrated sensitivity of ESR1 mutant cells to 
fulvestrant, a selective estrogen receptor downregulator, which was enhanced by the addition of 
IGF1R inhibitor96,97. 
1.3 STRATEGIES TO INHIBIT IGF1R ACTIVITY 
Due to the large body of preclinical evidence supporting the role of IGF1R signaling as a driver 
of cancer and mechanism of resistance to traditional cancer therapy (e.g. chemotherapy, 
radiation, endocrine, Her2-targeted therapy) numerous clinical trials have been initiated to 
evaluate the efficacy of inhibition of this pathway35,95,98,99. The clinicaltrial.gov database lists 
over 600 clinical trials in which IGF1 was cited as either a therapeutically targeted molecule or a 
diagnostic marker, and over 20 clinical trials reported specifically in breast cancer since 200835. 
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Clinical studies have used three main strategies thus far to inhibit IGF1R activation, including i) 
small molecule tyrosine kinase inhibitors (TKI) targeting the intracellular signaling domain of 
IGF1R, ii) monoclonal antibodies targeting the ligand binding domain of IGF1R, and iii) 
monoclonal antibodies targeting the IGF1/2 ligands33,35. However, while many Phase I/II studies 
have shown promising results, many Phase III studies have been largely negative or terminated 
early due to limiting toxicities and/or lack of efficacy35,100–102.  
1.3.1 Classes of anti-IGF1R therapies 
Most therapeutic agents developed were small molecule TKIs, such as OSI-906 or BMS-754807, 
that targeting the ATP-binding site of the β-subunit of IGF1R and thereby blocked intracellular 
signaling103,104.  However, these drugs displayed equal efficacy against InsR and HybR due to the 
high sequence and structural homology of the intracellular kinase domains of both receptors 
(nearly 100% in ATP-binding domain)33–35,104. Because of this, severe limiting toxicities (e.g. 
grade 3 and 4 metabolic syndrome and hyperglycemia) were reported in clinical trials due to the 
cross inhibition of InsR and insulin signaling, and many studies were terminated prematurely 
often without reporting results35,100. An alternative approach to inhibit IGF1R more specifically 
was with an anti-IGF1R monoclonal antibody, such as figitumumab (CP-751, 871), which 
targeted the ligand-binding domain of the receptor. In 2017, Ekyalongo and Yee estimated that 
over 50% of clinical trials in breast cancer targeting IGF1R have used this approach, with some 
trials still ongoing. However, many of the preliminary results to date from the Phase III trials 
from this class of agents have been negative, likely due to the lack of IGF1R expression in the 
tumor, or compensatory mitogenic signaling of InsR—the cost of a more specific 
therapeutic33,35,100.  
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 Ligand neutralizing (blocking) antibodies have been the least used approach to targeting 
IGF1R. These antibodies bind and neutralize IGF1/2 in circulation to block activation of IGF1R. 
Two antibodies in this class, MEDI-573 (MedImmune) and BI836845 (Boehringer Ingelheim) 
entered Phase II clinical trials in solid tumors, including breast cancer35. Pharmacodynamics data 
reported from the Phase I trial of MEDI-573 in solid tumors indicated that the antibody 
suppressed circulating IGF1/2, but did not result in a dose-limiting toxicity. Based on this data, 
the antibody moved into Phase II development and testing, specifically in late stage metastatic 
ER-positive breast cancers in combination with endocrine therapy (aromatase inhibitor 
[NCT01446159]). Unfortunately, MedImmune has recently discontinued development of their 
compound, citing safety and efficacy issues on their website. In contrast to MEDI-573 though, 
BI836845 was shown to increase circulating non-functional IGF1 levels (found in complex with 
the antibody), leading to anti-proliferative effects by blocking IGF1R activation105,106. Promising 
pre-clinical and Phase I data for BI836845 has supported its transition into Phase II trials in 
metastatic ER-positive breast cancer in combination with everolimus (mTOR inhibitor) and 
exemestane (aromatase inhibitor [NCT02123823]). Additional Phase I testing is now being 
completed to evaluate BI836845 in combination with abemaciclib (CDK4/6 inhibitor) and 
various additional endocrine therapies (NCT03099174), likely to increase potential future 
indications for clinical approval.  
1.3.2 Biomarker identification for response to anti-IGF1R therapy 
It seems intuitive that IGF1R targeted therapy would be selectively effective primarily in tumors 
expressing the target, and indeed pre-clinical studies have indicated that lack of receptor 
expression is a strong negative predictor of response to anti-IGF1R therapy. Despite this, many 
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clinical trials proceeded irrespective of IGF1R expression, and therefore may have been 
enrolling and treating patients that were inherently resistant to treatment33,107.  Supporting this, a 
study conducted in neuroblastoma cell lines treated with an IGF1R TKI (BMS-536924) 
identified high expression of IGF1R and IGF1/2 in sensitive cell lines, and high expression of 
IGFBP3/6 in resistant cell lines108. Additionally, anti-IGF1R antibody therapy lacked efficacy in 
breast cancer cells lacking expression of IRS1/2, further suggesting that activation of IGF1R in 
combination with expression of downstream signaling molecules is important in mediating 
response109. However, more comprehensive assessment is required to identify patients that would 
receive beneficial response from IGF1R targeted therapy.  
Studies evaluating changes in gene expression have sought to identify expression 
signatures indicative of IGF1 response in cancer cells and tumors with the overarching goal of 
selecting patients who may benefit to IGF1R targeted therapy87,110–112. As expected, gene 
expression changes induced by IGF1 in an immortalized breast epithelial cell line (184tert) were 
determined to regulate transcription, cell cycle, metabolism, and angiogenesis, and further these 
genes typically contained transcription factor binding sites for CRE/AP1/AP2 in conjunction 
with SP1 and ETS sites in the proximal promoter110. Similarly, a study from our lab showed that 
a set of greater than 800 genes were responsive to IGF1 stimulation in MCF-7 breast cancer 
cells, including genes regulating cell proliferation, survival, metabolism, and DNA repair 
pathways. This gene set was termed the IGF1-signature (IGF1-sig), and was then compared with 
gene expression profiles of multiple breast tumor cohorts. The IGF1-sig was found to correlate 
with the expression profiles of ER-negative breast tumors and a subset of ER-positive tumors 
that had low expression of ER. Additionally, the IGF1-sig correlated with pathologic features 
(e.g. high grade, larger tumors, nodal involvement) and poor overall patient survival112. In a 
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subsequent study, we observed that cell lines and xenograft models with high IGF1-sig were 
sensitive to anti-IGF1R therapy (BMS-754807) and that the IGF1-sig was reversed following 
treatment87. However, the IGF1-sig is likely similar to other growth factor pathway signatures 
and may not be sufficient to solely identify the patient populations that would benefit from 
IGF1R targeted therapy. Therefore, the goal of this project was to a complementary proteomics 
approach to gene expression profiling to determine novel mediators of IGF1R and InsR signaling 
with the goal of determining potential biomarkers for response to anti-IGF1R therapy.  
 17 
2.0  PROTEOMIC SCREENING AND LASSO REGRESSION REVEAL NOVEL 
REGULATORS OF THE IGF1 AND INSULIN SIGNALING PATHWAYS 
2.1 INTRODUCTION 
Activation of IGF1R and InsR have been shown to promote mammary tumorigenesis, metastasis, 
and resistance to anti-cancer therapy, and are associated with an increased risk for breast 
cancer73,74,81,90,92,98,113,114. However, although IGF1R inhibition has been effective in pre-clinical 
in vitro and in vivo studies, the receptor has proven difficult to specifically target in humans—
likely due to crosstalk with InsR and a lack of biomarkers for patient selection (see Chapter 
1)33,34,84,92,95,99,115. Understanding the relationship between the IGF1R and InsR signaling 
networks and their combined role in breast cancer is crucial to developing improved therapeutic 
strategies and a personalized medicine approach to oncology treatment. 
To gain insight and improved understanding of cellular signaling networks, such as the 
IGF1R and InsR pathways, an experimental methodology with the ability to track time-
dependent evolution of signaling is necessary. Technological advancements have led to the 
development of numerous proteomic approaches such as mass spectrometry116 and live cell 
imaging117 that allow for the quantification of multiple proteins across a large number of 
samples. Similarly, reverse phase protein array (RPPA) serves as a high-throughput technique 
that provides quantification of the expression of both phosphorylated and total proteins using 
validated antibodies118. This approach has previously been used for biomarker prediction119, 
classification of signaling response due to activation of upstream mediators120, and drug 
response121. Here, we used an RPPA data set obtained from a panel of 21 breast cancer cell lines 
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stimulated with IGF1 or insulin for a 48-hour time course to construct models of time-dependent 
signaling with the goal of characterizing differential signaling dynamics and interactions 
downstream of the two functionally similar growth factor signaling pathways. Finally, we 
validated two in silico predictions for novel mediators of the IGF1 and insulin growth factor 
signaling pathways: E-cadherin and acetyl-CoA carboxylase (ACC1/2). 
2.2 MATERIALS AND METHODS 
2.2.1 Cell culture and Reverse Phase Protein Array (RPPA) 
The data set (deposited in NCBI’s Gene Expression Omnibus (GEO) database with series 
accession number GSE80233) was generated at the RPPA Core Facility (MD Anderson Cancer 
Center, Houston, TX). Twenty-one breast cancer cell lines from the ATCC SPORE collection 
(AU565, BT20, BT474, Cama-1, HCC70, HCC1954, HS578T, MCF7, MCF10A, MDA-MB-
134-VI, MDA-MB-231, MDA-MB-361, MDA-MB-415, MDA-MB-435 (re-classified as 
melanoma cell line), MDA-MB-453, MDA-MB-468, SKBR3, T47D, UACC812, and ZR75.1) 
were cultured in complete growth medium consisting of DMEM, DMEM/F-12, RPMI, L15 or 
McCoy’s 5A with 10% FBS or horse serum according to the conditions provided by Neve et al. 
(Cancer Cell, 2006)122. Cells were plated in triplicate 6 cm dishes per treatment time point and 
then switched to serum-free medium (SFM). Cells were serum starved for 24 hrs, then treated 
with 10nM IGF1 (GroPep BioReagents #CU100) or insulin (Sigma #12643) for 5 min, 10 min, 
30 min, 6 hr, 24 hr, or 48 hrs. Cells treated with vehicle (Vhc) were collected at 5min, 24 hr, and 
48 hr.  
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Cell lysates were washed in ice-cold PBS twice, and lysed immediately in RPPA lysis 
buffer with protease inhibitor (1% Triton X-100, 50mM Hepes, 150mM NaCl, 1.5mM MgCl2, 
1mM EGTA, 100mM NaF, 10mM NaPPi, 10% Glycerol, 1mM Na3VO4, 1mM PMSF, 10ug/ml 
Aprotinin). Lysates were sonicated and centrifuged at 14,000 rpm at 4°C for 10 min. Protein 
concentrations were determined by BCA and lysates diluted to 1ug/ml final concentration with 
4X SDS/β-mercaptoethanol sample buffer. Each lysate was printed in duplicate with five 2-fold 
dilutions on a single nitrocellulose-coated FAST slide (945 lysates, printed 10 times; GE 
Healthcare). Then, each slide was probed with a primary antibody and a biotin-conjugated 
secondary antibody. Levels of 134 proteins or phospho-proteins were measured using 
corresponding antibodies. The signal, amplified by the Dako Cytomation-catalyzed system 
(Dako), was visualized by DAB colorimetric reaction. The slides were then scanned and 
quantified using Microvigene (VigeneTech) software. Super-curve fitting was used for loading 
correction of each sample123. Yu-fen Wang (graduate student), Dr. Beate Litzenburger 
(postdoctoral fellow) and Dr. Angelo Casa (postdoctoral fellow) completed the culturing, 
stimulation and lysis of cells in 2009 while our lab (PI: Dr. Adrian Lee) was located at Baylor 
College of Medicine (Houston, TX). 
2.2.2 Quality control of RPPA antibodies 
Internal quality control on the specificity and validity of the 134 antibodies used in the RPPA 
experiment was performed. Validation required obtaining a single or dominant band for the 
antibody in question on immunoblots run for the dynamic range of the RPPA data conditions. 
Pearson correlation coefficients of 0.8 between RPPA and immunoblot results were used as a 
cutoff to determine if the antibody was specific for the intended target. The RPPA Core Facility 
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routinely updates their list of available reliable antibodies based on experiences in hundreds of 
conditions and cell lines. With the combination of information from our experience and others, 
26 of the antibodies were labeled as “non-specific” under the specific experimental conditions, 
and were excluded from all subsequent analyses. 
2.2.3 Data processing and construction of linear statistical models 
Briefly, the data acquired from the RPPA experiment was pre-processed to reduce noise, and 
modeled using lasso regression to create predictions of IGF1 and insulin signaling interactions. 
Validation of models was completed using a synthetic data set and performance tested using a 
leave-one-out cross validation methodology. Statistical analysis on the validation experimental 
results were performed using Student’s t-test with significance level of p<0.05. All simulations 
and analyses were completed in Matlab, versions 2014a and 2015a (MathWorks).  Cemal Erdem 
(graduate student; laboratory of Drs. Timothy Lezon and D. Lansing Taylor in the Department of 
Computational and Systems Biology at the University of Pittsburgh) completed all 
computational biology methodology related to this study. Modeling predictions were then 
validated using wet-bench experimentation. Complete methods can be found in our Molecular 
and Cellular Proteomics publication (Erdem and Nagle et al. 2016, PMID: 27364358)124. 
2.2.4 Stable shRNA infection 
T47D cell line was acquired from ATCC and cultured in RPMI+10% FBS. Stable CDH1 
knockdown T47D cells were generated using a retro-viral infection of Renilla targeting control 
(shSCR [5’ TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTAT 
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AGTGAAGCCACAGATGTATAGATAAGCATTATAATTCCTATGCCTACTGCCTCGGA]) 
and CDH1 (shCDH1 [5’ TGCTGTTGACAGTGAGCGCAAGTGTGTTCATTA 
ATGTTTATAGTGAAGCC ACAGATGTATAAACATTAATGAACACACTTATGC 
CTACTGCCTCGGA]) short-hairpin RNAs (shRNA). Following infection, cells were selected 
using growth media supplemented with 1ug/ml Puromycin (Life Technologies #A11138-03) and 
were routinely cultured in the selection media. Dr. Tiffany Katz (post-doctoral fellow in the 
laboratory of Dr. Steffi Oesterreich) generated these cells. 
2.2.5 Transient siRNA knockdown 
MCF-7 cell line was acquired from ATCC and cultured in DMEM+10%FBS. MCF-7 cells were 
reverse transfected with either 50nM of ON-TARGETplus Non-targeting pool (Dharmacon #D-
001810-10) or 25nM each of SMARTpool ON-TARGETplus ACACA and ACACB (acetyl co-A 
carboxylase) siRNA (Dharmacon # L-004551-00 and L-004759-00) following the Lipofectamine 
RNAiMAX manufacturer’s protocol (Life Technologies #13778-150) for 48 hours.  
2.2.6 IGF1/insulin stimulation 
Cells were plated to approx. 70% confluency, serum starved overnight then stimulated with 
10nM HCl (Vhc), IGF1, or insulin for 5 min or 10 min time points as indicated. 
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2.2.7 Immunoblotting 
Samples for immunoblot analysis were collected using RIPA buffer (50mM Tris pH 7.4, 150mM 
NaCl, 1mM EDTA, 0.5% Nonidet P-40, 0.5% NaDeoxycholate, 0.1% SDS) supplemented with 
1x HALT protease and phosphatase cocktail (Thermo Fisher #78442), water bath sonicated for 
15 minutes (1 min on, 30 sec off), and centrifuged at 14,000rpm at 4˚C for 12 minutes. Protein 
concentration was assessed using BCA assay (Thermo Fisher #23225) and 50ug of protein per 
sample was run on 12% SDS-PAGE gel (except when blotting for ACC – then 7% SDS-PAGE 
gel was used) then transferred to PVDF membrane. Membranes were blocked for 1 hour using 
Odyssey PBS Blocking Buffer (LiCor #927-40000) then probed using the following primary 
antibodies and concentrations: pERK Thr202/Tyr204 (Cell Signaling #4377; 1:1000), total ERK 
(Cell Signaling #9102; 1:1000), pAkt S473 (Cell Signaling #4060; 1:1000), total Akt (Cell 
Signaling #9272; 1:1000), E-cadherin (BD Biosciences #610182; 1:1000), ACC1/2 (Cell 
Signaling #3676; 1:500) and β-actin (Sigma #A5441; 1:5000). Membranes were then washed in 
TBST, incubated in LiCor secondary antibody (1:10,000) for 1 hour (anti-rabbit 800CW [LiCor 




2.3.1 Large-scale proteomic screening of IGF1/insulin signaling in breast cancer cell lines 
To further our understanding of the IGF1 and insulin signaling networks using a systems biology 
approach, we performed a proteomic screen using reverse phase protein array (RPPA) on 
samples from 21 breast cancer cell lines of various histological subtypes. Cells were stimulated 
with vehicle (Vhc), 10nM IGF1, or 10nM insulin for six time-point analyses (5, 10, 30m, 6h, 
24h, 48h). RPPA analysis included 134 different antibodies against phosho- and total proteins. 
However, twenty-six antibodies were excluded from this study (see Methods), leaving a 
remaining set of 108 proteins for analysis. An overview of the data produced from the phospho-
antibodies revealed that IGF1 and insulin (data not shown) stimulation induced phosphorylation 
of IGF1R (pIGF1R) at Tyr1135/1136 in all cell lines (Figure 3). Additionally, maximal 
activation generally occurred at 5 – 10 minutes following stimulation and declined thereafter as 
expected. However, activation of downstream targets, such as Akt (pAkt) and phosphorylation of 
ribosomal protein S6 (pS6), following IGF1 stimulation was only observed in approximately half 
of the cell lines. The cell lines MCF-7, MCF10A, T47D, MDA-MB-134, MDA-MB-231, and 
ZR75.1 (among others) were found to be highly IGF1 responsive and exhibited maximal 








Figure 3: IGF1-induced phospho-protein expression profiles in 21 breast cancer cell lines. 
The heat map shown depicts the change in the expression of 28 phospho-proteins following a 48 hr time 
course of IGF1 stimulation as determined by RPPA analysis. Six columns are shown for each cell line, with 
each column representing a single time point (5, 10, 30 min, 6, 24, 48 h). The values shown represent the 
difference in log2 expression level relative to the serum-starved condition. Red color corresponds to up-
regulation and blue color represents down-regulation of signal compared relative to serum-starved cells. Row 
headings indicate the arrayed proteins with phosphorylation sites indicated after the subscript ‘p’. 
 
 
2.3.2 Time dependent modeling predicts novel mediators of IGF1 and insulin signaling 
We collaborated with Drs. Timothy Lezon and D. Lansing Taylor (and graduate student – Cemal 
Erdem), in the Department of Computational and Systems Biology at the University of 
Pittsburgh to develop a computational model to better understand the IGF1 and insulin signaling 
networks, and potentially determine differential mediators of these pathways. Work from their 
lab resulted in the development of a novel time dependent model based on lasso regression that 
when combined with perturbation analysis predicted mediators of IGF1 and insulin signaling. 
The result of the model consisted of the ‘perturbed’ protein that if altered under conditions of 
IGF1 and/or insulin stimulation affected the expression level of the ‘output’ protein. The output 
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was arbitrarily set as phosphorylated Akt (S473 or Thr308) and ERK (Th202/204) due to their 
roles as major downstream signaling hubs of pIGF1R/InsR. A depiction of the top exclusive 
interactions for IGF1 and insulin stimulation, as well as the top differential interactions revealed  
the complexity of the system (Figure 4). 
 
 
Figure 4: Computationally inferred network of signaling interactions in the IGF1/insulin pathways. 
The schematic depicts the signaling interactions inferred by the lasso regression computational model moving 
from the vehicle to the 10 min time-point of growth factor stimulation. The major downstream signaling hubs 
(pAkt (S473) and ERK (Th202/204)) are labeled in yellow (‘output’). The purple lines represent the top 20 
exclusive interactions present in IGF1 model only and the blue lines represent the interactions inferred only 
in the insulin model. The red lines represent the interactions present in both models, but with magnitudes 
stronger in the IGF1 model and the black lines also represent the interactions present in both models, but 
with higher magnitudes in the insulin model. 
 
 
Additionally, the computational model predicted the time point that the interaction was most 
evident and the ligand (IGF1 or insulin) predicted to have the greatest effect (Table 1) on 
signaling magnitude. The two signaling interactions predicted by the model that we focused on 
for this study, due to their novelty and potential impact, included i) E-cadherin regulation of 
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IGF1/insulin-induced Akt phosphorylation and ii) acetyl-CoA carboxylase (ACC1/2) regulation 
of IGF1/insulin-induced ERK phosphorylation.  
 
 
Table 1: In silico predictions for novel IGF1/insulin signaling mediators. 
The table depicts the top candidate predictions for novel IGF1 and/or insulin signaling interactions as 
predicted by the lasso regression computational model. Outlined are the ‘perturbed’ proteins that if altered 
may affect IGF1 and insulin signaling through Akt and ERK at the given time points. 
 
 
2.3.3 Validation of IGF1/insulin signaling mediators predicted in silico 
To validate these predictions, we used shRNA/siRNA knockdown of E-cadherin (CDH1) and 
acetyl-CoA carboxylase (ACACA/ACACB) in breast cancer cell lines, followed by stimulation 
with IGF1 and insulin to assess changes in downstream Akt or ERK signaling. Cell lines chosen 
for the experimental validation express both high levels of the protein target for knockdown and 
are IGF1/insulin responsive based on our proteomic data. First, the effect of E-cadherin loss on 
IGF1/insulin-induced Akt (S473) signaling was assessed. Following shRNA knockdown of 
CDH1 (shCDH1) in T47D cells, enhanced IGF1/insulin-induced phosphorylation of Akt 
following 5 and 10 min of stimulation was observed (Figure 5). The fold change induction of 
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pAkt (S473) over vehicle in shCDH1 cells was greater compared to control cells (shSCR) with 
stimulation of both growth factors at the 5 min time point (shCDH1 IGF1=9-fold [p<0.01]; 
shCDH1 insulin=4-fold [p<0.005]). Similarly, both IGF1 and insulin induced greater fold change 
induction in pAkt in shCDH1 cells compared to shSCR at the 10 min time point. The magnitude 
of change was greatest with IGF1 stimulation compared to insulin; therefore, we focused on the 
regulation of the IGF1 signaling pathway by E-cadherin for the remainder of the study (Chapters 




Figure 5: Knockdown of E-cadherin (CDH1) enhances IGF1- and insulin-induced Akt signaling. 
(A) T47D breast cancer cells stably expressing Renilla (shSCR) or CDH1 (shCDH1) shRNA were stimulated 
with IGF1 (10nM) for 5 or 10 min. Akt signaling (pAkt (S473) and total Akt) and levels of E-cadherin were 
assessed by immunoblot. (B) Quantification of immunoblot was done using LiCor software and is displayed 
as relative pAkt/Akt levels as a fold change over vehicle for each time point. Data shown is from one 
independent experiment with n=2 biological replicates. 
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Next, the effect of ACC1/2 knockdown in MCF-7 cells on IGF1/insulin-induced ERK 
signaling was assessed. The fold change induction of ERK signaling (pERK Th202/204) by 
IGF1 in cells with knockdown of ACC (siACC) was increased compared to siSCR cells at the 5 
min time point (siACC IGF1=3-fold increase (p<0.05) [Figure 6]). Conversely, the fold change 
induction of ERK signaling by insulin at the same time point in siACC cells was decreased 
compared to siSCR cells (siACC insulin=0.8-fold decrease (p<0.05)). Additionally, there was a 
trend toward down-regulation of pERK signaling in siACC compared to siSCR cells at the 10 




Figure 6: Knockdown of acetyl coA-carboxylase (ACC1/2) divergently alters IGF1- and insulin-
induced ERK signaling. 
(A) MCF-7 breast cancer cells transfected with scramble (siSCR) or ACC (siACC) siRNA were stimulated 
with IGF1 (10nM) for 5 or 10 min. ERK signaling (pERK (Th202/204) and total ERK) and levels of 
ACC1/2 were assessed by immunoblot. (B) Quantification of immunoblot was done using LiCor software 
and is displayed as relative pERK/ERK levels as a fold change over vehicle for each time point. Data 
shown is from one independent experiment with n=2 biological replicates. 
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2.4 DISCUSSION 
In the study presented in this chapter, we assessed the temporal dynamics of the IGF1 and insulin 
signaling pathways to identify differences in downstream signaling and uncover novel 
interacting mediators. We assessed the expression of 108 phospho- and total proteins in a large 
panel of breast cancer cell lines following IGF1 and insulin stimulation over a 48-hour time 
course using a high-throughput proteomic approach. A novel, unbiased computational model was 
then developed to understand how signaling interactions in the IGF1 and insulin growth factor 
pathways change over time, and to determine differential signaling components in these highly 
similar pathways. The model was internally validated in two ways using the inherent existence of 
post-translational modifications within the data: i) levels of non-phosphorylated protein predicted 
the ability of the same protein to become phosphorylated (e.g. PKCα and Rb1 [data not shown]) 
and ii) the presence of known interactions between kinase and substrate were observed (e.g. 
p70S6K levels predicted phosphorylation of S6 ribosomal protein [data not shown])124.  
Additionally, the model predicted in silico that alterations in E-cadherin and ACC1/2 affect Akt 
and ERK signaling, respectively, in IGF1 and insulin-stimulated cells, and these predictions were 
validated experimentally in vitro. The in vitro validations provide further confidence that future 
predictions of signaling mediators may be defined and validated successfully using this 
approach.  
Based on the in silico predictions, we show that the loss of E-cadherin in breast cancer 
cells enhances IGF1 and insulin-induced Akt signaling. The interaction of E-cadherin with 
IGF1/insulin signaling has high translational relevance for two reasons. First, E-cadherin is a 
critical regulator of epithelial to mesenchymal transition (EMT) and metastasis in breast cancer. 
One of the significant features of EMT is reduction in E-cadherin expression, combined with 
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increases in expression of the mesenchymal markers N-cadherin and vimentin83,125,126. While it 
has been established that IGF1-IGF1R signaling induces an EMT phenotype and drives E-
cadherin repression, the reverse regulation of signaling has not been well characterized81,83,84. 
Consistent with our findings, it has been shown that endogenous E-cadherin negatively regulates 
Akt signaling activation by sequestering β-catenin leading to increased PTEN transcriptional 
activation and decreased Akt phosphorylation127,128. Additionally, it has been demonstrated that 
overexpression of E-cadherin reduces growth factor-signaling activation by reducing both 
receptor mobility and ligand binding affinity129,130.  Further detail regarding the regulation of 
growth factor pathways by E-cadherin is discussed in Chapter 3.  
Second, invasive lobular carcinoma (ILC), a subtype of breast cancer accounting for 10-
15% of total breast cancer cases, is defined by loss of functional E-cadherin protein. This occurs 
in 90% of ILC and is frequently due to truncation mutations in CDH1, hemizygous deletion of 
the CDH1 locus, or transcriptional repression15. Our proteomic data indicates that an ILC cell 
line, MDA- MB-134, is one of the most IGF1 responsive cell lines used in the study (Figure 3). 
We focus on and highlight the importance of the IGF1-IGF1R pathway in ILC in Chapter 4.  
Additionally, we validate that the loss of ACC in MCF-7 cells divergently effects IGF1 
and insulin-induced ERK signaling. ACC is activated by phosphorylation of AMP-activated 
protein kinase (AMPK) and functions to catalyze the irreversible carboxylation of acetyl-CoA to 
produce malonyl-CoA to regulate a rate limiting step in fatty acid synthesis. Cancer cells often 
overexpress genes that regulate lipogenic signaling such as fatty acid synthase (FASN), stearoyl-
CoA desaturase (SCD1), and ACC1/2 to drive oncogenic signaling in low nutrient and highly 
oxidative tumor microenviornments131. Evidence suggests that the activation of AMPK, as a 
result of decreased hepatic glucose following treatment with the diabetes drug, metformin, 
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induces ACC levels leading to enhanced insulin signaling and reduced insulin resistance132. 
Despite this mechanism linking ACC to insulin signaling, we found no previously reported link 
between ACC and ERK signaling. Therefore, of note, there is no clear hypothesis for how this 
novel interaction influences IGF1 induction of ERK signaling.  
 In summary, although preclinical and epidemiological evidence suggest IGF1R to be a 
beneficial therapeutic target in breast cancer, the compensatory and activating feedback 
mechanisms in tumor cells have likely prevented the efficacy of anti-IGF1R/InsR therapy in 
clinical trials to date33,35,36. Only after understanding the dual IGF1R/InsR network dynamics, 
could we identify the tumor subclasses suitable for inhibition of this pathway. The computational 
model of the IGF/insulin signaling networks introduced in this study provide us with a 
framework to uncover novel experimental targets of pharmacological importance in these 
pathways. 
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3.0  LOSS OF FUNCTIONAL E-CADHERIN ENHANCES IGF1R SIGNALING IN 
BREAST CANCER 
3.1 INTRODUCTION 
IGF1 is a circulating endocrine peptide hormone that is a major regulator of organismal growth 
and development34. IGF1, in combination with estrogen, is essential for normal mammary gland 
development, and this pathway is deregulated in the initiation and progression of breast 
cancer133–136. Many studies, including from our laboratory, have shown the ability of IGF1 
receptor (IGF1R) to promote mammary tumorigenesis and metastasis both in vitro81,88 and in 
vivo81,90,92. Additionally, we showed that when constitutively activated, IGF1R transformed 
mammary epithelial cells, increased migration and invasion, and induced epithelial to 
mesenchymal transition (EMT) via the NFkB pathway and upregulation of Snail81,84.  
Based on these observations, both small molecule tyrosine kinase inhibitors and 
monoclonal antibodies against IGF1R were tested in clinical trials in breast cancer. 
Unfortunately, although as many as 50% of breast tumors express IGF1R52, these trials only 
identified a small subset of patients showing a therapeutic response to IGF1R targeted therapy, 
suggesting that predictive biomarkers are required to identify which patients’ tumors will be 
responsive33,35,36,137.  
We previously developed an IGF1-signature (IGF-sig) based on microarray analyses, and 
more recently reported on a novel computational method to identify putative biomarkers of IGF1 
signaling using a systems biology approach112,124. The latter was based on a proteomic screen 
using reverse phase protein array (RPPA) on 21 breast cancer cell lines of various histological 
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subtypes stimulated with IGF1 over a time course (discussed in Chapter 2)124. This 
computational model identified E-cadherin as a putative regulator of IGF1 signaling, and data in 
this chapter indicate that loss of E-cadherin expression directly increases IGF1R pathway 
activation and associated phenotypes in breast cancer.  Insight into how E-cadherin regulates 
IGF1R is necessary to aid in our understanding of the oncogenic signaling network, specifically 
because the loss of E-cadherin i) is implicated in the ability of tumor cells to escape the primary 
tumor to potentially seed metastatic lesions and ii) is transcriptionally repressed and/or 
genetically lost in subsets of breast tumors126,138–141. The latter will be discussed in depth in 
Chapter 4. 
3.2 MATERIALS AND METHODS 
3.2.1 Cell Culture 
All cell lines were authenticated (most recent date listed in [ ] below following each cell line) by 
the University of Arizona Genetics Core and mycoplasma tested (Lonza #LT07-418). Lab stocks 
were made following authentication and were used for this study. MCF-7 (ATCC; DMEM+10% 
FBS [06/29/16]), T47D (ATCC; RPMI+10% FBS [02/08/17]), ZR75.1 (ATCC; RPMI+10% 
FBS [10/13/16]), and MDA-MB-231 (ATCC; DMEM+10% FBS [10/13/16]) cells were cultured 
with indicated media conditions. Julie Scott (Oesterreich Lab) and Beth Knapick (Lee Lab) 
assisted with cell line propagation and authentication. 
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3.2.2 Transient siRNA knockdown 
Cells were reverse transfected with 25nM final concentration of siGENOME human 
SMARTpool control siRNA (Dharmacon #D-001206) or siGENOME human SMARTpool 
CDH1 siRNA (Dharmacon #M-003877-02) using standard Lipofectamine RNAiMAX 
(Invitrogen #13778) protocol. Downstream assays were typically performed 48-72 hours 
following transfection. For experiments involving IGF1 (GroPep BioReagents #CU100) 
stimulation, cells were serum starved overnight and then pulsed with IGF1 (1nM, 10nM, or 
100nM) for 10 minutes. 
3.2.3 Stable shRNA infection 
Stable CDH1 knockdown T47D cells were generated using a retro-viral infection of Renilla 
targeting control (shSCR [5’ TGCTGTTGACAGTGAGCGCAGGAATTAT 
AATGCTTATCTATAGTGAAGCCACAGATGTATAGATAAGCATTATAATTCCTATGCC
TACTGCCTCGGA]) and two CDH1 (sh-1 [5’ TGCTGTTGACAGTGAGCGCA 
AGTGTGTTCATTAATGTTTATAGTGAAGCCACAGATGTATAAACATTAATGA 
ACACACTTATGCCTACTGCCTCGGA] and sh-2 [5’ TGCTGTTGACAGTGAGCGA 
CCGGGACAACGTTTATTACTATAGTGAAGCCACAGATGTATAGTAATAAACGTTGTC
CCGGGTGCCTACTGCCTCGGA]) short-hairpin RNAs (shRNAs). Following infection, cells 
were selected using growth media supplemented with 1ug/ml Puromycin (Life Technologies 
#A11138-03) and were routinely cultured in the selection media. These cells were generated by 
Dr. Tiffany Katz (postdoctoral fellow, Oesterreich Lab). 
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3.2.4 Plasmid DNA overexpression 
MDA-MB-231 cells were stably transfected using FUGENE6 with empty or hE-cadherin-
pcDNA3 vector (Addgene #45769) using 15ug DNA per 10cm plate of cells. Cells were selected 
using growth media supplemented with 800ug/ml G418 (Invitrogen #10131-035) and were 
routinely cultured in the selection media until a stable population of cells grew out. 
3.2.5 Immunoblotting 
Samples for immunoblot analysis were collected using RIPA buffer (50mM Tris pH 7.4, 150mM 
NaCl, 1mM EDTA, 0.5% Nonidet P-40, 0.5% NaDeoxycholate, 0.1% SDS) supplemented with 
1x HALT protease and phosphatase cocktail (Thermo Fisher #78442), probe sonicated for 15 
seconds (20% amplitude), and centrifuged at 14,000rpm at 4˚C for 12 minutes. Protein 
concentration was assessed using BCA assay (Thermo Fisher #23225) and 50ug of protein per 
sample was run on 12% SDS-PAGE gel then transferred to PVDF membrane. Membranes were 
blocked for 1 hour using Odyssey PBS Blocking Buffer (LiCor #927-40000) then probed using 
the following primary antibodies and concentrations: pIGF1R Y1135 (Cell Signaling #3918; 
1:500), total IGF1R β-subunit (Cell Signaling #3027; 1:1000), pAkt S473 (Cell Signaling #4060; 
1:1000), total Akt (Cell Signaling #9272; 1:1000), E-cadherin (BD Biosciences #610182; 
1:1000), and β-actin (Sigma #A5441; 1:5000). Membranes were then washed in TBST, 
incubated in LiCor secondary antibody (1:10,000) for 1 hour (anti-rabbit 800CW [LiCor #926-
32211]; anti-mouse 680LT [LiCor #925-68020]), then imaged using the Odyssey Infrared 
Imager. 
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3.2.6 IGF1-induced cell cycle and viability analysis 
For cell cycle: MCF-7 and ZR75.1 cells were reverse transfected as described above for 48 
hours. Cells were then serum starved for 30 hours, and pulsed with 10nM IGF1 for 17 hours. 
Cells were then trypsinized, washed 2x with PBS, and fixed in 70% EtOH for 30 minutes at 4˚C. 
Cells were washed 2x with PBS then incubated in 50ng/ul RNase A (Qiagen #1007885) for 15 
minutes at 37˚C. Cell DNA content was then stained using 50ng/ul propidium iodide (Sigma 
#P4170) for 30 minutes at 4˚C. Cell cycle profiles were analyzed using the BD LSRII flow 
cytometer. Statistical difference in percent of cells in S- or G2/M phase in IGF1 treated cells 
over vehicle control in experimental groups was evaluated using a two-tailed student’s t-test 
(p<0.05). 
For viability: T47D short hairpin control (shSCR) and E-cadherin knockdown (shCDH1) 
cells were plated in serum-free media in 96 well plates (9,000 cells per well) and then stimulated 
with IGF1 (10nM) for 6 days. The FluoReporter Blue Fluorometric DNA content Quantitation 
Kit was used to measure dsDNA as a measure of cell viability. Statistical difference in Hoechst 
fluorescence in IGF1 treated cells over vehicle control in each cell line was evaluated using a 
two-tailed student’s t-test (p<0.05). 
3.2.7 Immunofluorescence microscopy and proximity ligation assay 
Cells were plated on coverslips for the assay and then fixed in 4% paraformaldehyde for 30 
minutes at 37˚C. Coverslips were washed 2x with PBS and then permeabilized for 1 hour using 
0.3% Triton X-100 diluted in PBS. For immunofluorescence, coverslips were blocked in 5% goat 
serum diluted in PBS and then incubated in primary antibody overnight (total IGF1R β-subunit 
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[Cell Signaling #3027; 1:300] and E-cadherin [BD Biosciences #610182; 1:100]), followed by 
Alexa Fluor secondary antibody incubation for 1 hour (anti-rabbit Alexa Fluor 488 [Life 
Technologies #A11070] and anti-mouse Alexa Fluor 546 [Life Technologies #A11018]; 1:200).  
Coverslips were imaged by confocal microscopy. 
For in situ proximity ligation assay, coverslips were processed using the Duolink red 
mouse/rabbit kit using the protocol provided (Sigma #DUO92101) with the same antibody 
dilutions as described above. Confocal microscopy was used for imaging. The ratio of 
puncta/nuclei for each experimental condition was calculated by counting all puncta and nuclei 
in five 60x images. One-way ANOVA was used to compare the ratios between the experimental 
conditions (VHC, 30m, 6hr, 24hr). 
3.2.8 Dose response growth assays  
MCF-7, ZR75.1 and T47D cells were reverse transfected with control or CDH1 siRNA as 
described above into 96-well plates (9,000 cells per well) in 100ul of media per well. The 
following day, cells were treated with 3x vehicle (DMSO), OSI-906 (Selleckchem #S1091) or 
BMS-754807 diluted in 50ul of media for a final volume in each well of 150ul (n=6 per 
concentration). Adherent and suspension plates (2D and ultra-low attachment [ULA; Corning 
#3474]) were collected on day 6 and viability was measured using CellTiter Glo Viability assay 
(Promega #G7572) according the manufacturer protocol. EC50 values for viability were 
calculated by non-linear regression and statistical differences evaluated using sum-of-squares 
Global f-test (p<0.05).  
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3.3 RESULTS 
3.3.1 Loss or inhibition of E-cadherin results in enhanced IGF1R activity 
To validate our previously published data (Chapter 2)124 and to further understand the regulation 
of the IGF1 signaling pathway by E-cadherin, we silenced E-cadherin (CDH1) by siRNA 
knockdown in a panel of three estrogen receptor (ER)-positive IDC cell lines and then stimulated 
with a dose series of IGF1 (0, 1, 10, 100nM). MCF-7, ZR75.1, and T47D E-cadherin knockdown 
(siCDH1) cells showed enhanced sensitivity to IGF1 compared to the scramble control (siSCR) 
cells, most notable at the 1nM dose of IGF1, resulting in increased levels of IGF1R and Akt 
phosphorylation (Figure 7A-C). As a complementary approach, we inhibited E-cadherin function 
in MCF-7 cells using the HECD-1 monoclonal antibody that binds the extracellular domain of E-
cadherin and prevents adherens junction formation. Similar to the knockdown of E-cadherin, 
HECD-1 treated cells showed increased IGF1R and Akt phosphorylation compared to control 
(Figure 7D). Additionally, we evaluated confluency-dependent IGF1R signaling to understand 
the effect of increased cell-cell contacts. A confluent monolayer of MCF-7 cells lost the ability to 
initiate IGF1R signaling upon ligand stimulation compared to a sub-confluent monolayer 
(approx. 50%), however, the knockdown of E-cadherin rescued this signaling in both confluency 
conditions (Figure 7E).  We evaluated the functional effect of enhanced IGF1 signaling by 
examining the effect of IGF1 on the cell cycle profile in MCF-7 and ZR75.1 cells with reduced 
E-cadherin. CDH1 knockdown cells showed a significant increase (p=0.03 and p=0.0005, 
respectively) in the percentage of cells progressing into the S- and G2/M-phases of the cell cycle 
following IGF1 treatment compared to the siSCR cells (Figure 7F). Similarly, slight increases in 
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IGF1-induced cell viability in E-cadherin knockdown cells compared to SCR in T47D cells were 
observed (Figure 25). 
We overexpressed E-cadherin in MDA-MB-231 cells, an ER-negative IDC cell line with 
undetectable E-cadherin protein by immunoblot to determine if overexpression represses 
signaling. Although adherens junction formation was not observed (data not shown), E-cadherin 
overexpressing cells demonstrated decreased phosphorylation of IGF1R and Akt compared to 
empty vector control cells, and significantly less cell cycle progression in response to IGF1 












Figure 7: Loss or inhibition of E-cadherin enhances IGF1R signaling. 
 (A) MCF-7, (B) ZR75.1, and (C) T47D breast cancer cells transfected with SCR (siSCR) or CDH1 (siCDH1) 
siRNA were stimulated with increasing doses of IGF1 (0-100nM) for 10 min. IGF1R and Akt signaling was 
assessed by immunoblot. Of note, IGF1R expression could routinely not be detected in ZR75.1. (D) MCF-7 
cells were treated with 25ug/ml HECD-1 antibody for 24 hours and imaged by phase-contrast microscopy 
for dissociation of adherens junctions. Cells were stimulated with Vhc or 10nM IGF1 for 10 min and IGF1R 
and Akt signaling assessed by immunoblot. (E) MCF-7 cells were plated at sub-confluency (200k cells in 6-
well) or high confluency (800k cells) and then stimulated with either Vhc or 10nM IGF1 for 10 min. IGF1R 
signaling was assessed by immunoblot. Representative phase-contrast microscopy images of the cell plating 
densities are shown. (F) MCF-7 and ZR75.1 siSCR and siCDH1 cells were serum-starved and stimulated 
with 10nM IGF1 for 17 hours and DNA stained with propidium iodide to measure cell cycle profile. The 
percent of cells in the IGF1/Vhc conditions in the S- and G2/M phases of the cell cycle for siSCR and siCDH1 
are shown (representative experiment shown; n=2 or 3 each with 3 biological replicates). 
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3.3.2 Loss of E-cadherin enhances sensitivity to IGF1R inhibition 
Due to the enhanced sensitivity of E-cadherin knockdown cells to IGF1 stimulation, we 
determined if loss of E-cadherin in ER+ IDC also increased sensitivity to the IGF1R ATP-
competitive small molecule inhibitors, OSI-906 (OSI) and BMS-754807 (BMS). Specifically, we 
tested the effect of loss of E-cadherin on sensitivity to OSI and BMS in MCF-7, ZR75.1, and 
T47D cells. In addition to 2D adherent culture, ultra-low attachment suspension growth (ULA) 
conditions was examined, since we observed increased cell viability in E-cadherin knockdown 
cells under these conditions (Tasdemir et al, manuscript in preparation), possibly due to the 
reported annoikis resistance of cells lacking E-cadherin expression142. MCF-7 siCDH1 cells 
displayed significantly decreased viability in response to OSI treatment, compared to siSCR cells 
in both 2D (p<0.0001; Figure 8A) and ULA (p=0.0003; Figure 8B) growth conditions resulting 
in a shift in the EC50. Additionally, ZR75.1 siCDH1 cells showed significantly decreased 
viability and a shift in the EC50 when grown in ULA (p<0.0001; Figure 27A-B) in response to 
OSI treatment, but not in the 2D growth condition. However, there was no change in viability 
between T47D siSCR and siCDH1 cells in response to OSI in either growth condition (Figure 
28A-B).  
Similarly, MCF-7 and T47D siCDH1 cells showed decreased viability in response to 
BMS compared to siSCR cells grown in the ULA growth condition (p<0.0001 and p<0.05, 
respectively), but no significant difference in 2D (Figure 8C-D, Figure 28C-D). However, 
ZR75.1 siCDH1 cells did not display enhanced sensitivity to BMS compared to siSCR cells in 
either growth condition (Figure 27C-D). Overall, these data suggest that the loss of E-cadherin 
enhances breast cancer cell sensitivity to IGF1R inhibition. We also tested the growth response 
of MCF-7 siSCR and siCDH1 cells treated with ICI 182,780 (ICI), a selective estrogen receptor 
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downregulator (SERD), and observed no statistical difference in EC50 suggesting that the loss of 
E-cadherin does not generally sensitize cells to all small molecule drug treatments (Figure 29). 
 
 
Figure 8: Knockdown of E-cadherin increases sensitivity to IGF1R inhibition. 
MCF-7 cells were reverse transfected with SCR or CDH1 siRNA and seeded into 96-well 2D or ULA plates 
and treated with IGF1R inhibitor (OSI-906 or BMS-754807) for 6 days. Conditions in the panels as follows: 
(A) OSI-906; 2D, (B) OSI-906; ULA, (C) BMS-754807; 2D, (D) BMS-754807; ULA. The CellTiter Glo 
assay was used to assess cell viability (relative luminescence). EC50 values for viability were calculated by 
non-linear regression and statistical differences evaluated using sum-of-squares Global f-test (p<0.05; 
representative experiment shown; n=3 each with 6 biological replicates). 
 
 
3.3.3 IGF1R and E-cadherin directly interact in ER+ breast cancer cells resulting in 
recruitment of IGF1R to adherens junctions 
To understand how E-cadherin regulates IGF1R, we assessed whether IGF1R and E-cadherin 
directly interact in breast cancer cells using in situ proximity ligation assay (PLA). The 
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sensitivity and specificity of PLA allows for detection of endogenous interacting proteins within 
proximity of no further than 40nm. Because the protocol requires probes to be within nanometer 
proximity for effective ligation and signal detection, it is suggested that both primary antibodies 
bind in the same orientation to the proteins of interest, either extracellular or cytoplasmic.  
Therefore, using a rabbit IGF1Rβ cytoplasmic subunit antibody and a mouse E-cadherin 
cytoplasmic antibody, PLA showed that IGF1R and E-cadherin directly interact in both MCF-7 
and T47D cells, as shown by the red fluorescent puncta (Figure 9A-B). To demonstrate the 
specificity of the detection, we used MCF-7 knockdown cells lacking E-cadherin (siCDH1) or 
IGF1R (siIGFR) as negative controls, stained for E-cadherin and IGF1R, and observed the red 
fluorescent puncta signal greatly diminished (Figure 9C-D, Figure 30A-C).  
 
 
Figure 9: Proximity ligation assay reveals a direct interaction between IGF1R and E-cadherin. 
(A) MCF-7 and (B) T47D cells were plated on coverslips, fixed, and stained with IGF1R and E-cadherin 
antibody overnight. The Duolink (Sigma) in situ PLA protocol was followed and coverslips were imaged 
using confocal microscopy to reveal red puncta. (C) MCF-7 siCDH1 and (D) siIGF1R cells were used as 
negative controls for the assay to assess primary antibody specificity. 
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Additionally, the specificity of the secondary antibodies was confirmed by using each primary 
antibody alone and a no primary antibody control and did not detect significant levels of PLA 
puncta over background (Figure 30D-F). The interaction between IGF1R and E-cadherin 
following IGF1 stimulation was examined using PLA. In MCF-7 cells, IGF1 treatment (30 min, 
6 hr, 24 hr) caused a significant decrease in number of fluorescent puncta (p=0.003), suggesting 
that the interaction between the two proteins needs to be disrupted for proper IGF1R function 
(Figure 10A-E). This possibly explains why siCDH1 cells have an increased IGF1R signaling 
capacity compared to control cells. We stained MCF-7 cells for endogenous IGF1R and E-
cadherin and determined that IGF1R and E-cadherin co-localize to adherens junctions.  
 Interestingly, co-localization was prominent at the points of cell-cell contact, and 
noticeably absent or reduced on portions of the membrane where there was no cell-cell contact 
(Figure 11A). This suggests that E-cadherin recruits IGF1R to adherens junctions, perhaps to 
sequester the receptor as a mechanism of signaling repression. Upon knockdown of E-cadherin 
the expression pattern of IGF1R appears to redistribute equally to the entire cell membrane 




Figure 10: IGF1 stimulation induces the disruption of the IGF1R-E-cadherin complex. 
MCF-7 cells were plated on coverslips and treated with either (A) Vhc or 10nM IGF1 for (B) 30 min, (C) 6 
hr, or (D) 24 hr using PLA protocol. (E) Red puncta and nuclei (DAPI) were quantified and displayed as a 
ratio of puncta/nuclei. All puncta and nuclei in 60x images were counted (n=5). Statistical difference 
determined by one-way ANOVA (p<0.05; representative experiment shown). Data shown is from 1 




Figure 11: IGF1R and E-cadherin co-localize at points of cell-cell contact. 
MCF-7 (A) siSCR and (B) siCDH1 cells were plated on coverslips, fixed, and stained with IGF1R and E-
cadherin antibody overnight.  The co-localization of IGF1R (green) and E-cadherin (red) was analyzed by 









Despite a large body of preclinical evidence supporting the use of IGF1R inhibitors for the 
treatment of breast cancer, the outcomes of clinical trials testing the efficacy of these drugs in 
patients thus far have been disappointing. However, these trials proceeded with a lack of 
appropriate biomarkers for predicting positive therapeutic efficacy and little to no understanding 
of which tumor types would benefit33,35,36,143. In response, in recent years the field has 
emphasized the need to understand and identify gene expression or proteomic biomarkers that 
predict a positive response to targeted therapy. Along this thought process, we previously 
published a gene expression signature used to identify tumors that are IGF1 responsive112 and 
here we focus on one proteomic biomarker, E-cadherin, identified through an integrative 
computational approach recently published by our group124. It is known that constitutive IGF1R 
activation drives E-cadherin transcriptional repression through EMT via NFκB induction of 
Snail81,84, however, the reverse regulation of IGF1R by E-cadherin has not been previously 
characterized. Our data suggest that loss of E-cadherin in breast tumors highlights a subset of 
tumors that may be responsive to IGF1R inhibition, and we begin to describe the mechanism by 
which this regulation occurs. 
We demonstrate that in breast cancer cells, IGF1R in breast cancer cells is endogenously 
localized to cell-cell contacts, similarly to data published by in MCF-7 cells overexpressing 
IGF1R144 and in corneal epithelial cells145. We show a direct, endogenous interaction between 
IGF1R and E-cadherin using in situ proximity ligation assay. To our knowledge interaction 
between IGF1R and E-cadherin in breast cancer cells has only been demonstrated by 
immunoprecipitation (IP)144. Our data provide confirmation of this interaction using a technique 
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known to be higher in specificity and sensitivity with less cell manipulation (e.g. cell lysis or 
scraping), compared to IP which often results in pull-down of entire protein complexes. This data 
suggests that IGF1R is recruited to adherens junctions by E-cadherin, possibly resulting in 
receptor sequestration and signaling repression.  
This process is similar to the sequestration of EGFR into the adherens junction and the 
subsequent loss of receptor mobility, a well characterized mechanism of EGFR signaling 
repression129,130,146. However, that action is suggested to be mediated through the tumor 
suppressor, Merlin, responsible for coordinating stabilization of the adherens junction and 
thereby regulating contact-inhibition growth146. Although IGF1R signaling is controlled in a 
contact-dependent manner (Figure 7E), Curto et al. additionally showed that IGF1 activity is not 
regulated by Merlin, indicating that IGF1R regulation by E-cadherin likely occurs independently 
of this factor146. Although there may be a yet undefined intermediate regulator similar to Merlin, 
our data indicate that E-cadherin plays a role in coordinating the recruitment and sequestration of 
IGF1R within the adherens junction and functions to inhibit IGF1R signaling. When E-cadherin 
is lost and junction formation is disrupted (such as in ILC cells discussed in Chapter 4), IGF1R is 
released and re-localizes to the entirety of the cell membrane where signaling is more easily 
initiated upon IGF1 ligand binding.  
Supporting this concept, our data indicate that the knockdown of E-cadherin in three ER+ 
breast cancer cell lines not only enhanced IGF1-induced signaling via IGF1R but also increased 
sensitivity of the cells to ligand. This is similar to the relationship reported between EGF-EGFR 
and IGF1-IGF1R upon adherens junction disruption via calcium-depletion130. Because of the 
increased IGF1R pathway activation and proliferative phenotype associated with the loss of E-
cadherin, the knockdown cells in turn became more sensitive to IGF1R inhibition. In our 
 49 
previous work we described sensitivity of ER-negative breast tumors to IGF1R inhibition (BMS-
754807)87, specifically mesenchymal-like triple negative tumors lacking expression of E-
cadherin147. However, we did not find a direct correlation between EC50 of BMS-754807 and E-
cadherin expression level in cell lines upon recent re-analysis of the data (data not shown). This 
suggests that multiple biomarkers may need to be used in combination, such as in combination 
with activation of the IGF1 gene signature, or perhaps there is a threshold by which E-cadherin 
expression in IDC tumor cells needs to be below to predict response to IGF1R inhibitor; a subset 
of ER-negative cells may be below that threshold.  
In summary, we present a diverse set of data indicating that the loss of E-cadherin 
enhances IGF1R pathway activity and sensitivity to anti-IGF1R therapy. We show that IGF1R 
and E-cadherin directly interact, and this leads to the sequestration and potential repression of 
IGF1R within the adherens junction. Overall, this study begins to shed light on a previously 
unrecognized mechanism of IGF1R regulation by E-cadherin and highlights a potential 
therapeutic strategy of exploiting the IGF1R pathway in breast cancer subtypes with low E-
cadherin expression. 
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4.0  HYPERACTIVE IGF1-IGF1R PATHWAY IN INVASIVE LOBULAR BREAST 
CARCINOMA PRESENTS A NOVEL THERAPEUTIC STRATEGY 
4.1 INTRODUCTION 
The data presented in Chapter 3 suggests that a loss of functional E-cadherin enhances IGF1R 
pathway activation leading to a hyperproliferative phenotype and increased sensitivity to IGF1R 
inhibition. Therefore, we hypothesize that subsets of breast cancer with diminished E-cadherin 
expression may be susceptible to IGF1R pathway inhibition.  
One such subtype of breast cancer with lack of E-cadherin expression is invasive lobular 
breast carcinoma (ILC), accounting for 10-15% (~30,000 cases/year in the United States) of total 
breast cancer cases. ILC is defined by the loss of functional E-cadherin (CDH1), which occurs in 
95% of ILC due to truncating mutations, loss of heterozygosity, and transcriptional 
repression14,15. Due to the loss of E-cadherin protein, ILC cells grow in linear patterns throughout 
the breast tissue, lacking the ability to form adherens junctions, in contrast to the solid mass 
growth of the most frequent subtype of breast cancer, invasive ductal breast carcinoma (IDC)16. 
Interestingly, one of the most IGF1 responsive cell lines in our proteomic data set (Chapter 2) 
was an ILC cell line, MDA-MB-134, that lacks E-cadherin protein expression and cell-cell 
junctions124.  In this chapter, we characterize the IGF1-IGF1R pathway activity in ILC, and 
provide evidence that inhibition of IGF1R in E-cadherin deficient breast cancers, such as ILC, 
could potentially serve as an effective therapeutic strategy. 
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4.2 MATERIALS AND METHODS 
4.2.1 Cell Culture 
All cell lines were authenticated (most recent date listed in [ ] following the cell lines below) by 
the University of Arizona Genetics Core and mycoplasma tested (Lonza #LT07-418). Lab stocks 
were made following authentication and were used for this study. MDA-MB-134-VI (ATCC; 
50/50 DMEM/L15+10% FBS [02/08/17]), SUM44PE (Asterand; DMEM/F12+2% CSS with 
5ug/ml insulin, 1ug/ml hydrocortisone, 5mM ethanolamine, 5ug/ml transferrin, 10nM 
triodothyronime, and 50nM sodium selenite [02/08/17 – no reference profile exists in database]), 
and BCK4148 (MEM+5% FBS with 1nM insulin and 1x NEAA [10/13/16 – no reference profile 
exists in database) cells were cultured with indicated media conditions. BCK4 cells were kindly 
provided by Dr. Britta Jacobsen (UC Denver). Julie Scott (Oesterreich Lab) and Beth Knapick 
(Lee Lab) assisted with cell line propagation and authentication. 
4.2.2 Immunoblotting 
Samples for immunoblot analysis were collected using RIPA buffer (50mM Tris pH 7.4, 150mM 
NaCl, 1mM EDTA, 0.5% Nonidet P-40, 0.5% NaDeoxycholate, 0.1% SDS) supplemented with 
1x HALT protease and phosphatase cocktail (Thermo Fisher #78442), probe sonicated for 15 
seconds (20% amplitude), and centrifuged at 14,000rpm at 4˚C for 12 minutes. Protein 
concentration was assessed using BCA assay (Thermo Fisher #23225) and 50ug of protein per 
sample was run on 12% SDS-PAGE gel then transferred to PVDF membrane. Membranes were 
blocked for 1 hour using Odyssey PBS Blocking Buffer (LiCor #927-40000) then probed using 
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the following primary antibodies and concentrations: pIGF1R Y1135 (Cell Signaling #3918; 
1:500), total IGF1R β-subunit (Cell Signaling #3027; 1:1000), E-cadherin (BD Biosciences 
#610182; 1:1000), and β-actin (Sigma #A5441; 1:5000). Membranes were then washed in TBST, 
incubated in LiCor secondary antibody (1:10,000) for 1 hour (anti-rabbit 800CW (LiCor #926-
32211); anti-mouse 680LT (LiCor #925-68020)), then imaged using the Odyssey Infrared 
Imager. 
4.2.3 Immunofluorescence microscopy 
Cells were plated on coverslips for assay then fixed in 4% paraformaldehyde for 30 minutes at 
37˚C. Coverslips were washed 2x with PBS and then permeabilized for 1 hour using 0.3% Triton 
X-100 diluted in PBS. Coverslips were blocked in 5% goat serum diluted in PBS and then 
incubated in primary antibody overnight (total IGF1R β-subunit [Cell Signaling #3027; 1:300] 
and E-cadherin [BD Biosciences #610182; 1:100]) followed by Alexa Fluor secondary antibody 
incubation for 1 hour (anti-rabbit Alexa Fluor 488 [Life Technologies #A11070] and anti-mouse 
Alexa Fluor 546 [Life Technologies #A11018]; 1:200). Confocal microscopy was used for 
imaging. 
4.2.4 Dose response growth assays and synergy experiments 
SUM44PE and MDA-MB-134-VI cells were plated in 96-well ULA plates (Corning #3474; 
18,000 cells per well) in 100ul of media per well. The following day, cells were treated with 6x 
vehicle (DMSO), OSI-906, BMS-754807, or BEZ235 (Selleckchem #S1009) diluted in 25ul of 
media such that the combination of two drugs resulted in 150ul of total volume in each well (n=2 
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per experiment). Plates were collected on day 6 and viability was measured using CellTiter Glo 
Viability assay (Promega #G7572) according to the manufacturer’s protocol. Synergy was 
calculated using the Median-Effect Principle and Combination Index-Isobologram Theorem 
(Chou-Talalay)149 using the computer program Calcusyn (Biosoft, Cambridge, UK). Values less 
than one indicate synergistic drug interactions. Combination index values for ED50, ED75, 
ED90 are shown as a mean ± SEM from n=3 independent experiments. 
4.2.5 In vivo ILC xenograft growth and explant culturing 
MDA-MB-134, BCK4, and WHIM9150 cells (5x106 cells) were injected into the right inguinal 
mammary fat pads of NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG; The Jackson Laboratories 
[MM134 and WHIM9]) or CB17.Cg-PrkdcscidLystbg-J/Crl (SCID-beige; Charles River [BCK4]) 
mice, respectively (implanted with slow release estradiol (0.36mg) pellet [Innovative Research of 
America #SE-121]) and collected at a tumor volume of approximately 350mm3. Tumors were then 
collected, processed, and minced into 1-2mm3 chunks of tumor tissue. Julie Scott (Oesterreich 
Lab) assisted with tissue implantation, harvesting, and processing. Tissue chunks were then plated 
on Vetspon Absorbable Hemostatic Gelatin sponges (Patterson Veterinary #07-849-4032) in 12-
well tissue culture plates containing 1.5mls of explant media (DMEM/F12+10% FBS with 10mM 
HEPES, 1mg/ml BSA, 10ug/ml insulin, 10ug/ml hydrocortisone, 1x antibiotic-antimycotic 
solution (Thermo Fisher #15240-062)). Explant media conditions were provided by Dr. Damir 
Vareslija (PI: Dr. Leone Young). Media was treated with vehicle or 1uM BMS-754807 or 100nM 
BEZ235 for 72 hours. Tissue chunks were collected by formalin fixation followed by paraffin 
embedding. Sections were stained for ki67 (Dako #M7240; 1:100) as a marker of proliferation 
using standard immunohistochemistry technique. Nuclei were quantified by counting all clearly 
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defined nuclei within each explant tissue section (n=3-8). A two-tailed student’s t-test was used to 
determine statistical difference between vehicle and BMS treatment or a one-way ANOVA to 
determine the difference between vehicle, BMS, and BEZ treatment (p<0.05). Justin Kehm and 
Kara Burlbaugh (undergraduates; Lee and Oesterreich Labs) assisted with quantification of Ki67 
staining. 
4.2.6 TCGA data analysis 
TCGA RNA-Sequencing (RNA-seq) expression data were downloaded as transcripts per million 
(TPM) from the Gene Expression Omnibus database (GEO: GSE62944) and log2(TPM+1) for 
gene-level results were used. TCGA Reverse Phase Protein Array (RPPA) data were downloaded 
as median-normalized, batch-corrected expression values from TCPA (Level 4, version 4.0). ER+ 
IDC (n=417) and ILC (n=137) samples with both RNA-Seq and RPPA data were used for all 
analyses. Mann-Whitney U tests were used to compare expression, Spearman’s rho to compare 
correlations, and a chi-square test to compare proportions between ILC and IDC tumors. All were 
calculated using R (version 3.4.1). The median expression values for IGF1 and pIGF1R across 
ER+ IDC and ILC tumors (n=554) for correlation were used as cutoffs. Kevin Levine (graduate 
student; Oesterreich Lab) completed all bioinformatic analysis. 
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4.3 RESULTS 
4.3.1 Invasive lobular breast cancer (ILC) displays enhanced IGF1-IGF1R pathway 
activation 
Because knockdown or inhibition of E-cadherin induces hyperactivity of the IGF1R pathway in 
cell line models, we investigated whether IGF1R pathway activity is also hyperactivated in ILC, 
a subtype of breast cancer that accounts for 10-15% of all breast cancer cases and is molecularly 
classified by its genetic loss of E-cadherin15. Because 90-95% of ILC tumors are ER+ we 
focused on this cohort15. IGF1R expression and localization was examined in the ER+ ILC cell 
lines: SUM44PE (Figure 12A), MDA-MB-134 (Figure 12B), and BCK4 (Figure 12C). As 
expected, ILC cells showed a lack of membranous E-cadherin staining. Additionally, IGF1 
signaling response in a panel of ILC cell lines (MM134, SUM44PE, BCK4, and MM330) was 
compared to MCF-7 cells, which is thought of as the most highly IGF1 responsive breast cancer 
cell line.  Of note, MM330 cells express E-cadherin protein, but harbor alterations in α-catenin 
rendering their adherens junctions non-functional and therefore, are classified as an ILC cell line. 
The ILC cells displayed a greater or equal level of phosphorylation of IGF1R in response to 








Figure 12: ILC cell lines express membranous IGF1R 
(A) SUM44PE, (B) MDA-MB-134, and (C) BCK4 ILC cells were immunostained for IGF1R (green) and E-
cadherin (red) and imaged by confocal microscopy. Nuclei were stained with Hoechst. Of note, BCK4 cells 
were imaged at an increased exposure compared to MM134 and SUM44PE cells. 
 
 
To compare IGF1R activity in ER+ ILC (n=137) and IDC (n=417) tumors, CDH1 and 
IGF1 ligand mRNA expression, and IGF1R phosphorylation (pIGF1R; Y1135/Y1136) were 
examined using RNA-sequencing and Reverse Phase Protein Array data from The Cancer 
Genome Atlas (TCGA). Concurrent with a decrease in CDH1 mRNA expression (p=9.06e-52; 
Figure 13A), IGF1 ligand mRNA expression (p=1.3e-15; Figure 13B) and pIGF1R levels 
(p=2.15e-08; Figure 13C) were significantly increased in the ILC tumors compared to IDC 
tumors. Interestingly, ILC tumors exhibited a significant positive correlation (Spearman 
rho=0.21; p=0.012), despite having significantly reduced total IGF1R expression compared to 
IDC (data not shown; Figure 13D). In contrast, IDC tumors did not show a correlation 
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(Spearman rho=0.06; p=0.22) suggesting that presence of IGF1 ligand did not necessarily 
activate IGF1R in IDC. Strikingly, the percentage of tumors with higher than median expression 
(across all breast tumors) of both IGF1 and pIGF1R is significantly higher in ILC (56.2%) 
compared to IDC (21.3%), suggesting that IGF1 ligand activates IGF1R signaling in these 
tumors more efficiently with the loss of E-cadherin (chi-square test, p= 2.5e-14; Figure 13D). 
Interestingly, when assessing activation of the IGF-sig112 (gene signature indicative of active 
IGF1 signaling) in ER+ ILC versus IDC in the TCGA cohort we did not observe a statistically 
significant difference in expression score (data not shown). 
 
 
Figure 13: IGF1-IGF1R pathway is active in ILC with genetic loss of E-cadherin 
(A) CDH1 mRNA, (B) IGF1 mRNA, (C) and pIGF1R Y1135 & Y1136 levels in ER+ IDC compared to ER+ 
ILC in TCGA were plotted using RNAseq (log2 TPM+1) and RPPA (median normalized) data. The TCGA 
cohort includes n=417 IDC cases and n=137 ILC cases that have matched data for RNAseq and RPPA. Man-
Whitney test was used to determine significant differences in expression level between the two subtypes 
(p<0.05). (D) Correlation between pIGF1R and IGF1 ligand expression is plotted for IDC (left) and ILC 
(right). Spearman’s rank correlation was used to demonstrate the correlation between the two variables with 
significance as defined by p<0.05. Bioinformatic analysis was completed by Kevin Levine (Oesterreich Lab). 
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4.3.2 IGF1R inhibitors and endocrine therapy synergize to decrease viability in ILC cells 
Clinically, patients with ER+ ILC are treated with endocrine therapy targeting ER, however, data 
from the BIG 1-98 trial suggest that ILC tumors demonstrate resistance to tamoxifen therapy 
compared to IDC22. Additionally, results from multiple clinical studies indicate that ILC patients 
have a poorer prognosis with more frequent late recurrences compared to IDC 19,23,24. This 
highlights the need to improve therapeutic options in ILC patients based on uniquely activated 
pathways and therefore, we evaluated efficacy of IGF1R pathway inhibitors in ER+ ILC cell 
lines in combination with endocrine therapy. Recent data published from our lab suggest that 
tamoxifen, a selective estrogen receptor modulator (SERM), can act as a partial ER agonist 
activating ER activity in some ILC cell lines, rather than a pure antagonist as in IDC cells151, in 
line with the data from the BIG1-98 study. Therefore, we tested efficacy of the SERD, ICI 
182,780 (ICI) in combination with two IGF1R inhibitors used in Chapter 3 (OSI and BMS) and a 
PI3K/mTOR inhibitor (BEZ235 (BEZ)) in our studies. SUM44PE and MM134 cells were treated 
with increasing doses of OSI (Figure 14A-B; Figure 32A-B), BMS (Figure 14C-D; Figure 32C-
D), and BEZ (Figure 14E-F; Figure 32E-F) in combination with increasing doses of ICI. With all 
three IGF1R pathway inhibitors decreased cell viability was observed with the addition of 
increasing doses of ICI. Formal testing the synergy of the drug combinations using the Median-
Effect Principle and Combination-Index Isobologram Theorem, commonly referred to as the 
Chou-Talalay method149 revealed combination index (CI) values less than 1 for drug interactions 
at the ED50, ED75, and ED90 indicating a high level of synergy for the three sets of inhibitor 
combinations (Figure 14, Figure 32, Table 3). The lowest CI values were observed for the 
BMS+ICI drug combination in SUM44PE cells (ED50=0.127, ED75=0.081, ED90=0.099). 
Additionally, a minimum dose reduction index (DRI) for ICI of 8-fold for all drug combinations 
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in SUM44PE cells and 2-fold in MM134 cells at the EC50 was seen. This data suggests that 
adding an IGF1R pathway inhibitor in combination with ICI reduces the concentration of ICI 






Figure 14: IGF1R pathway inhibitors and endocrine therapy synergize to inhibit cell viability in ILC 
SUM44PE ILC cells were plated into 96-well ULA plates and treated for 6 days with increasing doses of (A, 
B) OSI-906, (C, D) BMS-754807, or (E, F) BEZ235 in combination with increasing doses of ICI 182,780. 
The dose response curves and heat maps shown indicate inhibition of cell viability (relative luminescence 
measured using CellTiter Glo). Representative experiment shown; n=3 independent experiments each with 
2 biological replicates per combination of doses. 
 61 
4.3.3 Ex vivo IGF1R pathway inhibition inhibits proliferation in ILC xenografts 
Finally, we evaluated the efficacy of an IGF1R inhibitor in ILC in vivo. However, there are a 
limited number of ILC patient-derived xenograft (PDX) and cell line xenograft models, and their 
slow growth rates makes large scale in vivo studies challenging. We therefore treated two ILC 
cell line xenografts and one ILC PDX ex vivo as explant cultures, as previously described from 
our lab and others152–155. The advantages of this technique include less tissue requirement for the 
assay compared to an in vivo study and rapid understanding of the therapeutic efficacy of the 
inhibitor. Additionally, data published by Majumder et al.155 suggest a high concordance 
between ex vivo and in vivo tumor response to drug treatment. MM134 and BCK4 cells (a 
weakly ER responsive ILC cell line, not used for synergy experiments due to slow growth in 
vitro) were grown as xenografts, harvested and plated as explant culture, and then treated the 
media with vehicle or BMS (1µM) for 72 hours. The tissue was collected and stained for Ki67 as 
a marker of proliferation. We observed a significant decrease in Ki67 positive nuclei in both 
tumor models treated with BMS (Figure 15). In the MM134 tumor we observed a significant 
decrease (p=0.002) in Ki67 positive nuclei from 47% in the vehicle to 22% in the BMS treated 
tumor tissue (n=3 or 4; Figure 15A-C). Similarly, in the BCK4 tumor we observed a significant 
decrease (p=0.005) in Ki67 positive nuclei from 25% in vehicle to 11% in BMS treated tumor 
tissue (n=6; Figure 15D-F).  
In addition to the cell line xenografts, the ER+ ILC PDX, WHIM9, was treated with 
BMS and BEZ as an explant. Because this tumor harbors a PIK3CA hotspot mutation (H1047R), 
inhibition of the PI3K pathway using BEZ was included150. We observed a trend toward a 
decrease in Ki67 positive nuclei from 27% in the vehicle to 23% in the BMS treated tumor 
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tissue, and observed a significant decrease (p<0.01) in to 8% in BEZ treated tumor tissue (n=7 or 
8; Figure 33). This data suggests that targeting the IGF1R pathway in ILC tumors may be a 







Figure 15: IGF1R inhibition reduces proliferation in ILC tumor ex vivo cultures. 
MM134 and BCK4 xenograft tumors were harvested from immunocompromised mice, minced into 1-2mm3 
tumor chunks and then plated on gelatin sponges in 12-well plate containing 1.5ml media. Media was treated 
with DMSO Vhc or 1uM BMS-75807 for 72 hours. Tumor pieces were harvested by FFPE and stained for 
Ki67 as a marker of proliferation (A-B, MM134; D-E, BCK4). Staining was quantified by counting all clearly 
defined nuclei in 20x images (C and F). Statistical difference was assessed using a Student’s t-test (p<0.05; 
n=3-6). Ki67 staining quantification was completed by Justin Kehm and Kara Burlbaugh (undergraduates; 




We believe that the IGF1-IGF1R signaling may be particularly important in ILC, an 
understudied subtype of breast cancer, due to the complete loss of E-cadherin protein and/or 
adherens junction formation. In this subtype, the loss of E-cadherin may serve as a biomarker of 
IGF1 activity. Indeed, we demonstrate that ILC have increased IGF1 pathway activation (IGF1 
ligand expression and pIGF1R levels) compared with IDC. This is similar to the results of two 
studies analyzing differences between ILC and IDC that found increased IGF1 ligand and IGF1R 
expression levels in ILC20,156.  Consistent with this, we found that ILC cell lines are susceptible 
to IGF1R inhibition and importantly, that IGF1R pathway inhibitors (OSI, BMS, BEZ) synergize 
with a standard of care endocrine therapy (ICI) resulting in further reduced cell growth. Future 
studies will focus on validating these therapies in additional ILC tumors and understanding the 
synergistic interaction between IGF1R inhibitors and ICI. This data may be especially 
meaningful due to the fact that there is an increased prevalence of late recurrences in ER+ ILC 
compared to ER+ IDC tumors treated with endocrine therapy, indicating the need for improved 
therapy options for patients with ILC22,23. 
One limitation for the use of IGF1R inhibitors in ILC is the relatively high prevalence of 
mutations in the PI3K/Akt signaling pathway. Recently, Ciriello et al. comprehensively 
characterized ILC tumors compared to IDC tumors and described the mutational landscape of 
127 ILC tumors15. They found 48% of ILC tumors harbor hotspot/missense mutations in 
PIK3CA and 13% to carry either a truncating/missense mutation or high level copy number loss 
in PTEN, similar to what had been previously described20,21. These genetic alterations likely lead 
to the high Akt activity in these tumors as defined by an Akt signature they reported. Our data 
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suggest that the remaining tumors may also have high Akt signaling activity due to aberrant 
IGF1R activity. But, because the alterations in PIK3CA/PTEN occur downstream of IGF1R, the 
effectiveness of IGF1R inhibition in this setting is unclear, as demonstrated in Figure 33. 
Resistance to other upstream kinase inhibitors in tumors harboring activating alterations in 
PIK3CA/PTEN has been previously observed157 and therefore, it would be important to screen 
patients for these alterations before considering use of receptor tyrosine kinase inhibitor therapy, 
including against IGF1R.  
Interestingly, the use of an Akt pathway inhibitor, such as BEZ235, may be mutually 
beneficial in targeting the PIK3CA/PTEN alterations and the enhanced IGF1R pathway 
activation observed in these tumors. Cantley and colleagues recently reported that high levels of 
insulin promote resistance to PI3K inhibitors in tumors with PIK3CA mutations158, and therefore 
there may be a role for combinatorial IGF1R and PI3K inhibition as well. Future studies will 
investigate these relationships using additional ex vivo or in vivo screening of ILC tumors. 
Overall, this study begins to shed light on a previously unrecognized mechanism of IGF1R 
regulation by E-cadherin and highlights a potential therapeutic strategy of exploiting IGF1R 
pathway activity in ILC tumors. 
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5.0  DEVELOPMENT OF AN IGF1-DRIVEN TRANSGENIC MODEL OF ILC 
5.1 INTRODUCTION 
A major roadblock to ILC research is the lack of appropriate in vivo models that accurately 
recapitulate disease observed in humans. These models are required for improved mechanistic 
understanding of disease initiation and progression, and the development of novel therapeutic 
strategies to target ILC. The currently available models, similar to other types of cancer, include 
cell line xenografts, patient derived xenografts (PDX), and transgenic models. However, there are 
major drawbacks to many models currently available in the ILC field, as described below. 
Importantly, a common problem with in vivo models of ILC, similar to all breast cancer models, 
in that it is challenging to develop and sustain ER-positive (ER+) disease159,160. Due to the fact that 
approximately 90% of all ILC tumors are ER+, the presence and functionality of ER is a crucial 
aspect of the in vivo models used in research studies15. 
The use of cell line and patient derived xenograft models of ILC relies exclusively upon 
the ability of the cells or tissue to grow within an immunocompromised mouse, and this process is 
often lengthy in time or inefficient (e.g. low-take rates of tumors or large number of cells required) 
for ILC. Currently, we have only three ER+ cell lines available for use in cell line xenograft studies 
that are also markedly estrogen responsive (SUM44PE, MDA-MB-134, BCK4). Data from our 
lab (Tasdemir et al. unpublished) suggests that these cell lines may take up to five months to form 
palpable tumors of 350-500mm3 in size. Additionally, these mice need to be treated with estrogen 
pellet supplementation to support tumor growth, causing bladder and kidney toxicity resulting in 
loss of mice from the study prior to tumor formation. In addition to cell line xenografts, there are 
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a select number of ER+ ILC PDX models available for use, but similar to cell lines many have 
slow growth rates and low take-rates. Among the available ER+ ILC PDXs, there are differences 
in tumor growth rate, mutational status (ER, PIK3CA, p53), and estrogen dependence among these 
models. The select PDXs (e.g. WHIM20, WHIM23) with increased growth and/or take rate are 
highly proliferative, and therefore do not mimic the typical low proliferative rate of classic ILC 
found in patients15. The availability of an ER+ ILC PDX model is study dependent based on the 
tumor characteristics required. 
The overall use of xenograft models allows for the understanding of mechanisms for 
disease progression and response to therapeutics, but these models are not best suited for studies 
focused understanding tumor initiation and formation. In contrast, transgenic mouse models of 
ILC allow this, along with understanding of disease progression and response to therapeutics. 
Multiple models of mouse ILC have been developed, mainly by Drs. Jos Jonkers and Patrick 
Derksen, some with tumor latencies shorter than or equal to that required for xenograft 
studies142,161–163. 
Initial studies in the field of transgenic ILC mouse modeling, began with an unrelated study 
by Boussadia and Kemler, et al (2002)164, in which they assessed the effect of loss of E-cadherin 
on mammary gland development and remodeling following pregnancy, lactation, and involution. 
Using an MMTV-Cre driven recombination of floxed E-cadherin alleles (MMTV-Cre;CDH1flox), 
E-cadherin was inactivated in the differentiated alveolar cells of the mammary gland. While the 
mammary glands of female mice with homozygous somatic inactivation of E-cadherin developed 
normally up to 18 days of pregnancy, following parturition the mammary gland underwent massive 
apoptosis resulting in a lack of milk protein production and inability of dams to nurse pups. This 
resembled the status of the normal gland during involution when total remodeling via apoptosis is 
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in process. Further, this study suggests that the loss of E-cadherin function in the mammary gland 
is not sufficient to induce mammary tumorigenesis in mice.  
Despite the lack of tumor formation in the MMTV-Cre;CDH1flox model, Derksen and 
Jonkers et al. (2006) developed the first transgenic mouse ILC model using a similar Cre-
recombination based strategy142. However, they combined somatic inactivation of the tumor 
suppressor, p53 with the inactivation of E-cadherin, hypothesizing that the p53 inactivation would 
protect the cells with homozygous loss of E-cadherin from apoptosis-induced cell death leading to 
the formation of mouse ILC (mILC). The model they developed used a K14-driven Cre-
recombinase (K14Cre;CDH1flox;TRP53flox). Using this model, the authors confirmed the results 
of the study described above from Boussadia and Kemler et al. (2002), such that K14Cre;CDH1fl/fl 
mice did not exhibit the formation of mammary gland tumors. As expected, the loss of p53 alone 
(K14Cre;TRP53fl/fl) induced development of both non-metastatic skin and mammary tumors with 
a tumor latency of 330 days. Excitingly, the introduction of homozygous CDH1 floxed alleles 
(K14Cre;CDH1fl/fl;TRP53fl/fl) to create the triple transgenic model resulted in significantly 
decreased tumor latency (214 days), increased metastatic capacity, and led to changes in tumor 
phenotype. Mammary tumors from this genotype were described as mILC due to their histological 
similarity with human ILC. The authors described the cells as large, discohesive spindle shaped 
cells with pleomorphic nuclei expressing epithelial markers, but unfortunately, the tumors did not 
express ER. Additionally, it is estimated that only 8% of ILC tumors harbor alterations in TP53, 
rendering this model potentially applicable for studying only a small subset of the disease. 
In a second study, Derksen and Jonkers et al. (2011) developed a nearly genetically 
identical model of mILC, except they used the Wap promoter, rather than the K14 promoter. The 
authors indicate that the main benefit to switching the promoter was to circumvent the high number 
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of skin tumors produced by driving tumorigenesis on the K14 non-specific epithelial promoter161. 
The Wap (whey acidic protein) promoter is expressed in the luminal compartment of the mammary 
gland and while the promoter is most highly active during lactation, low basal activation occurs. 
Consistent with the previously published data, WapCre;CDH1fl/fl female mice did not develop 
mammary tumors, despite multiple rounds of pregnancy, and WapCre;CDH1fl/fl;TRP53fl/fl mice 
developed ER-negative mILC tumors with pleomorphic features with a median latency of 194 
days. Interestingly, inducing lactation did not affect tumor onset, latency, or metastatic formation 
in WapCre;CDH1fl/fl;TRP53fl/fl mice, indicating that the basal activity of the Wap promoter was 
sufficient to induce mILC tumor formation. 
In 2016, Boelens and Jonkers et al. published a novel strategy to develop a mILC transgenic 
model, following the comprehensive profiling of ILC in The Cancer Genome Atlas (TCGA)15. 
TCGA data suggest that at least 13% of ILC tumors harbor alterations in PTEN resulting in 
enhanced PI3K/Akt signaling activation. However, an additional 48% of tumors harbor activating 
alterations in PIK3CA also resulting in hyperactivation of the PI3K/Akt pathway. Therefore, the 
development of a novel mILC model to mimic PI3K/Akt activation as a tumor driver would 
potentially represent as many as 61% of total ILC cases. To do this, the authors followed a similar 
strategy as used by Derksen and Jonkers et al. (2011), except they replaced somatic inactivation 
of TRP53 with inactivation of PTEN163. This resulted in a WapCre;CDH1fl/fl;PTENfl/fl mouse that 
developed mILC with a tumor latency of 109 days. Consistent with previous findings, the authors 
note that WapCre;CDH1fl/fl mammary gland display enhanced apoptotic activity, reinforcing the 
idea that somatic inactivation of E-cadherin alone is not sufficient to induce tumor formation. 
However, they do disclose that these mice develop hyperplastic and dysplastic ducts filled with 
discohesive cells by 6 weeks of age, a phenotype not previously reported, prior to the gland 
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undergoing apoptosis. Importantly, the mILC tumors that develop in the 
WapCre;CDH1fl/fl;PTENfl/fl mice express ER in 26% of tumor cells, a marked improvement from 
the ER-negative p53 model previously developed. However, to our knowledge the functionality of 
ER in this model has yet to be assessed. A summary of the mILC transgenic models of note are 
found in Figure 16. 
Due to the lack of comprehensive mILC transgenic models, including models of ER+ 
disease, we sought to develop a novel model of ER+ mILC using the data we generated indicating 
hyperactivation of the IGF1-IGF1R pathway in ILC. The IGF1 transgenic mice (BK5.IGF1) 
constitutively overexpress IGF1 driven by the myoepithelial K5 promoter leading to numerous 
phenotypes including the development of skin and mammary tumors via paracrine IGF1-IGF1R 
signaling78,79. While mammary tumor formation is enhanced with DMBA treatment, BK5.IGF1 
female mice develop ER+ mammary tumors with an incidence of 31% by 55 weeks of age without 
treatment78. Aside from tumor formation, the BK5.IGF1 transgenic pups are often small, weak and 
developmentally delayed compared to wild-type pups. Their phenotype includes, scruffy skin, and 
acromegalic features, such as: enlarged paws, snout, and ears. Therefore, we are currently 
developing a model that mimics the breeding schemes of the previously above-described 
transgenic models, but using overexpression of IGF1 in combination with WapCre-driven somatic 
inactivation of E-cadherin to induce tumor formation. 
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Figure 16: Summary of currently available mILC transgenic models. 
Descriptions include genetic background of transgenic mice, type of mILC formed, reference to primary 
publication, and frequency of alteration as found in human ILC. 
5.2 MATERIALS AND METHODS 
5.2.1 Development of WapCre;CDH1flox transgenic mouse line 
We ordered the WapCre mouse165 from the NCI Mouse Repository (strain #01XA8). There is no 
cost associated with obtaining mice from the NCI Mouse Repository, however this process was 
quite lengthy because the stain was cryoarchived and required recovery prior to shipment. We 
received 1 female and 2 male B6.Cg-Tg(WAP-Cre)11738M mice and 1 male and 2 female 
C57BL/6NCr (wild-type) mice on 8/25/2015. The breeders that were sent to our animal facility 
were contaminated with MNV (mouse norovirus) and therefore pups generated between a wild-
type/transgenic breeding pair needed to be cross-fostered. Following cross-fostering and 
quarantine, the colony was expanded and maintained as a hemizygous colony. All WapCre 
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transgenic colonies are maintained with hemizygous WapCre expression because it is not possible 
to determine hemi- from homozygous positive mice based on genotyping. The mice were tail 
snipped and ear tagged at the time of weaning for genotyping. The following primer set was used 
to verify WapCre expression: forward 5' TAG AGC TGT GCC AGC CTC TTC and reverse 5’ 
CAT CAC TCG TTG CAT CGA CC. This primer set is labeled as “WAP”. Detailed information 
on the protocol used for genotyping, including PCR settings, can be found at the NCI Mouse 
Repository webpage. The WapCre PCR product appears as a 210bp band on a DNA gel following 
PCR. 
We ordered the CDH1flox transgenic mouse (B6.129-Cdh1tm2Kem/J) from Jackson 
Laboratories (Stock #005319). These mice were additionally cryoarchived and required recovery 
prior to shipment. We received heterozygous CDH1flox mice from Jackson Labs. The colony was 
expanded and mice were tail snipped and ear tagged at weaning for genotyping. The following 
primer set was used to determine CDH1flox allele status: forward 5' GGG TCT CAC CGT AGT 
CCT CA and reverse 5’ GAT CTT TGG GAG AGC AGT CG. This primer set is labeled as “IMR”. 
Detailed information on the genotyping protocol used, including PCR settings, can be found at the 
Jackson Labs webpage. The CDH1wt allele PCR product appears as a 243bp band and the CDH1fl 
allele product appears as a 310bp band on a DNA gel following PCR.  
To create the WapCre;CDH1wt/fl mouse needed for our studies, we crossed (cross #1) the 
WapCre mouse with the CDH1wt/fl mouse (Figure 17).  This mouse was on the C57BL/6 
background. Following the creation of the double transgenic mouse (WapCre;CDH1wt/fl), we 
backcrossed the C57BL/6 transgenic mouse three generations into a FVB/N background using 
mice purchased from Taconic. This was necessary due to the low penetrance of mammary tumors 
in C57BL/6 mice; FVB/N are known to have higher mammary tumor penetration in transgenic 
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models induced by multiple oncogenes166,167. Three backcrosses into FVB/N resulted in the “3rd 
backcross (bc) FVB” WapCre;CDH1wt/fl transgenic line that was 87.5% FVB/N and 12.5% 
C57BL/6. These mice were genotyped using the primers described above. This work was initiated 
by Dr. Tiffany Katz, a postdoctoral fellow in Dr. Steffi Oesterreich’s laboratory in 2015. 
 
 
Figure 17: Genetic cross (cross #1) required to produce WapCre;CDH1flox double transgenic strain. 
Depiction of the Mendelian genetics (Punnett squares) associated with the cross between WapCre x 
CDH1wt/fl mouse lines to produce the WapCre;CDH1wt/fl strain. The genotype of interest is highlighted in 
bold; additional genotypes not highlighted were euthanized. 
 
5.2.2 BK5.IGF1 transgenic mice 
We imported the BK5.IGF1 transgenic mouse line as a collaboration with Dr. Robin Fuchs-Young, 
an investigator at Texas A&M (originally developed by DiGiovanni and Kiguchi et al. (2000)79). 
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These mice do not to be genotyped due to the evident phenotype as described above. Additionally, 
they have the capacity to lose heat due to expression of the IGF1 transgene constitutively in their 
skin, and the MWRI veterinarian, Dr. Sara Andux, also suggested that these mice may be 
hypersensitive the light. This line is typically maintained by breeding through the male. Although, 
female BK5.IGF1 mice can breed successfully, due to the phenotype, cycling in the female is 
irregular results in inefficient and unpredictable breeding. The only downfall to this strategy is that 
only approximately 50% of male BK5.IGF1 mice are able/willing to mate. Additionally, the 
breeding life of these mice is considerably shortened compared to a wild-type animal – 
approximately 6-8 months of reliable breeding. The colony is maintained as a hemizygous colony 
by breeding male BK5.IGF1 mice with female outbred CD-1 mice ordered from Envigo. 
5.2.3 Breeding scheme for development of IGF1-driven mILC model 
WapCre;CDH1wt/fl (3rd backcross FVB/N) female mice were crossed with male BK5.IGF1 mice 
(cross #2; Fig 18). This mating resulted in 8 genotypes of mice with a combination of one of each 
of the three transgenes: 1) WapCre- or WapCre+, 2) CDH1wt/wt, or CDH1wt/fl, and 3) IGF1- or 
IGF1+.  
We then bred female WapCre;CDH1wt/fl;IGF1- and male WapCre;CDH1wt/fl;IGF1+ mice obtained 
from cross #2 to produce the “IGF1-ILC” tumorigenesis study cohort (cross #3; Figure 19). All 
other unused pups from cross #2 were euthanized. This mating resulted in 12 genotypes of mice 
with a combination of one of each of the three transgenes: 1) WapCre- or WapCre+, 2) CDH1wt/wt, 
CDH1wt/fl, or CDH1fl/fl, and 3) IGF1- or IGF1+. All male and WapCre- pups were euthanized from 
cross #3. Once the females in this cohort reach(ed) breeding age, they are mated for one cycle of 
pregnancy to induce maximal Wap promoter expression. Nursing of pups occurs for 5-8 days, and 
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then pups are euthanized to initiate mammary gland involution. Females in the cohort that do not 
become pregnant are indicated, such that potential differences in tumor formation or latency can 
be monitored.  Julie Scott and Beth Knapick assisted with colony maintenance, cage weaning, and 
weekly palpation. Scientific management of the IGF1-ILC mILC project will be transitioned to 








Figure 18: Genetic cross (cross #2) required to produce WapCre;CHD1flox;IGF1 triple transgenic 
mouse strain. 
Depiction of the Mendelian genetics (Punnett squares) associated with the cross between 
WapCre;CDH1wt/fl (female) x BK5.IGF1 (male) mouse lines to produce the triple transgenic 
WapCre;CDH1wt/fl;IGF1. The genotypes of interest are highlighted in bold (pink=female, blue=male); 




Figure 19: Genetic cross (cross #3) required to produce the cohort of female mice for the IGF1-ILC 
tumorigenesis study. 
Depiction of the Mendelian genetics (Punnett squares) associated with the cross between 
WapCre;CDH1wt/fl;IGF1- (female; pink) x WapCre;CDH1wt/fl;IGF1+ (male; blue) mouse lines to produce 
the triple transgenic female pups for the mILC tumorigenesis study . The genotypes of interest are 






We anticipate that female mice of the WapCre;CDH1fl/fl;IGF1+ genotype may potentially develop 
mILC due to the somatic inactivation of E-cadherin combined with activation of the oncogenic 
IGF1-IGF1R pathway. We anticipate the tumors to be ER+ because the mammary gland tumors 
formed in the BK5.IGF1 transgenic females are ER+78. To date, we have not observed tumor 
formation, likely because the cohort has not reached optimal age (oldest female in cohort born 
9/29/2017). Table 2 describes the total number of female mice in the IGF1-ILC tumor cohort to 
date (current as of 03/01/2018) per each of the six genotypes. We are continuing to breed (cross 
#3 repeated) to expand this cohort. Mice are currently monitored for tumor formation by palpation 
once per week. 
 
Table 2: Summary table outlining current number of female mice of each genotype in the IGF1-ILC 
tumorigenesis cohort. 
In bold (WapCre;CDH1fl/fl;IGF1+) is the genotype we anticipate may develop mILC. Number of animals is 





Due to the lack of ER+ mILC transgenic models, the development of novel mILC model would 
benefit the ILC research community in total. Importantly, this would be the first mILC transgenic 
model to use growth factor activation of oncogenic signaling in combination with somatic 
inactivation of E-cadherin to drive tumor formation. The ability of IGF1 to induce ILC tumor 
initiation and progression would indicate the importance of the IGF1-IGF1R signaling pathway in 
this disease. This would shed light on a possible mechanism of ILC development, providing insight 
on novel targets and therapeutic strategies. Additionally, because the increased IGF1 mRNA in the 
model mimics the increased mRNA levels observed in ILC from TCGA (discussed in Chapter 4), 
this would validate our research findings that the loss of E-cadherin enhances IGF1R activity and 
that the IGF1-IGF1R signaling axis is hyperactivated in human ILC. 
This model could be used to understand the potential for use of IGF1R inhibitors in the 
treatment of ILC. New strategies of inhibiting the IGF1-IGF1R axis are currently in progress. One 
such strategy in development is the use of an IGF1/2 ligand neutralizing antibody (BI 836845, 
Boehringer Ingelheim) to prevent IGF1/2 ligand binding to activate the IGF1R and downstream 
signaling105,106. BI 836845 is a fully humanized antibody that has high affinity IGF1/2. In 
preclinical studies, this drug has been shown to reduce phosphorylation of IGF1R and inhibit 
cancer cell proliferation. In vivo, BI 836845 treatment induces high levels of serum inactive IGF1 
and elevated growth hormone (GH) levels. Elevated GH levels indicate an endocrine site of action 
for the compound, and therefore, our model (if successful) would be useful to assess the capacity 
of the antibody to inhibit signaling induced by paracrine IGF1 in mammary tumors. We have a 
signed MTA with Boehringer Ingelheim, and anticipate being able to complete a study to address 
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this question. To our knowledge, this has not yet been tested and the site(s) of mechanism of action 
of the neutralizing antibody, BI 836845, are not comprehensively understood.  
 81 
6.0  CONCLUSIONS 
IGF1R signaling acts as a major mediator for normal mammary gland development and the 
progression to breast cancer. Pre-clinical evidence suggests that IGF1R activity drives malignant 
transformation in mammary epithelial cells and induces tumor growth and metastasis in murine 
models34,52,64,81. However, despite the vast amount of in vitro and in vivo evidence suggesting 
that targeting IGF1R in breast cancer would be a clinically beneficial therapeutic option, the 
results of clinical trials thus far using anti-IGF1R therapeutics have been largely 
unsuccessful33,35. This is thought to be mainly due to the lack of predictive biomarkers or criteria 
for beneficial response to therapy, and therefore, patients were not selected in a meaningful 
manner—often without confirmation that the tumor even expressed IGF1R. Additionally, due to 
IGF1R pathway crosstalk with insulin signaling, many therapeutics (e.g. receptor tyrosine kinase 
inhibitors) non-specifically inhibited InsR inducing metabolic syndrome in patients leading to 
dose limiting toxicities35. Recently, however, an innovative class of anti-IGF1R therapy, IGF1/2 
ligand binding antibody, have been initiated in pre-clinical studies and clinical trials in breast 
cancer. This therapeutic strategy inhibits IGF1/2 ligand binding to IGF1R to inhibit oncogenic 
signaling and importantly, seems to exhibit reduced side effects compared to previously used 
IGF1R/InsR tyrosine kinase inhibitors and anti-IGF1R monoclonal antibodies35,105,106. The 
advancement of the IGF1/2 ligand antibody, BI836845 (xentuzumab, Boehringer Ingelheim) into 
Phase 2 clinical trials presents a unique opportunity to develop biomarkers for response to anti-
IGF1R therapy to optimize and refine the subsets of patients that would most highly benefit from 
treatment. 
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 Along this thought process, our goal was to define novel proteomic biomarkers of IGF1 
and insulin signaling. Using a large proteomic screen in a panel of twenty-one breast cancer cell 
lines stimulated with IGF1 and insulin we developed an innovative computational model to 
predict signaling mediators. Through this process we identified a list of candidate proteins, 
including E-cadherin (CDH1) and acetyl coA-carboxylase (ACC1/2), thought to regulate IGF1- 
and insulin-induced Akt and ERK signaling, respectively124. In Chapter 2 we provide in vitro 
validation of the computational predictions, and focus on the negative regulation of IGF1 
signaling by E-cadherin. The predicted association between E-cadherin and IGF1 signaling was 
of interest due to the role of E-cadherin in epithelial to mesenchymal transition (EMT), thought 
to be a major regulator of cancer cell metastasis. Our lab and others have previously published 
studies describing the repression of E-cadherin by IGF1 signaling via activation of EMT 
programming. The reverse negative regulation of IGF1R by E-cadherin has been largely 
uncharacterized. This finding reveals a novel concept whereby the interaction between IGF1R 
and E-cadherin may be controlled by a feed forward loop—with the loss of E-cadherin activating 
IGF1R signaling via EMT programming, which further downregulates E-cadherin expression 
leading to cancer phenotypes (Figure 20). 
 Our studies, described in Chapter 3, indicate that the loss or functional inhibition of E-
cadherin enhances IGF1R pathway activation and results in increased IGF1-induced cell cycle 
progression and proliferation. Due to this, E-cadherin knockdown cells showed increased 
sensitivity to anti-IGF1R treatments compared to control cells. We additionally found that E-
cadherin directly regulates IGF1R, as the two proteins were found in complex endogenously by 
proximity ligation assay in breast cancer cells and co-localize at the adherens junction. This 
suggests that IGF1R is recruited to points of cell-cell contacts by E-cadherin as a method of 
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growth factor signaling repression, similar to a mechanism of repression described for 
EGFR129,130,146.  In summary, this data suggests that IGF1R has an increased signaling capacity 
when E-cadherin expression is diminished. Future studies will focus on fully understanding the 
mechanism of IGF1R signaling repression by E-cadherin, including i) determining whether a 
repressive signaling hub, containing negative regulators of IGF1R, is formed upon IGF1R 
association with E-cadherin, ii) determining whether there is a shift in the binding kinetics of 
IGF1 ligand to IGF1R in the presence or absence of E-cadherin, and iii) determining the specific 
domains of E-cadherin that are responsible for mediating IGF1R signaling (e.g. extracellular 
domain or p120 binding domain).  
 Importantly, a histological subtype of breast cancer termed invasive lobular carcinoma 
(ILC) displays loss of function E-cadherin protein in approximately 95% of total cases14,15. We 
hypothesized that this subtype may display hyperactive IGF1R signaling and investigated this 
association in Chapter 4. Because 90% of ILC tumors are ER+, we focused on this molecular 
subtype during our analyses15. Using gene expression and proteomic data from The Cancer 
Genome Atlas (TCGA) we determined that both IGF1 ligand mRNA expression and pIGF1R 
levels were enhanced in estrogen receptor-positive (ER+) ILC tumors compared to invasive 
ductal carcinoma (IDC) tumors, parallel with a significant decrease in CDH1 mRNA expression. 
This is similar to work published by Nakagawa et al. and Bertucci at al. that demonstrated 
increased IGF1 ligand expression in ILC compared to IDC tumors20,156. Further, we determined 
that ILC cell lines displayed increased IGF1-induced IGF1R phosphorylation compared to the 
IDC cell line, MCF-7, classically referred to as the most highly IGF1 responsive breast cancer 
cell line. IGF1 is typically produced in the stroma by fibroblasts and immune cells, and a recent 
study by Ireland and colleagues demonstrated high expression of IGF1/2 secreted from tumor-
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associated macrophages30,31,53–55—a significant point because ILC cells are surrounded by 
increased levels of stroma compared to IDC, rendering increased IGF1 ligand availability in this 
tumor type14,156. The availability of ligand in the stromal compartment may specifically 
contribute to the hyperactivation of IGF1R in ILC in contrast to activation of other receptor 
tyrosine kinases, such as EGFR, where the EGF ligand is not overexpressed (data not shown 
[TCGA]). 
Further, we showed that ER+ ILC cell lines and xenografts are sensitive to IGF1R 
inhibition, and in combination with endocrine therapy show synergistic inhibition of cell 
viability. Therefore, our data suggest that targeting IGF1R may be appropriate in this setting due 
to the hyperactivity of the IGF1-IGF1R pathway and ability to couple to existing endocrine 
therapy. This is a striking and clinically relevant finding because although ILC tumors are treated 
with endocrine therapy, patients with this disease suffer increased incidence of endocrine therapy 
resistance and more late recurrences compared to IDC, as demonstrated by multiple clinical 
studies19,22–24. Therefore, there exists a unique challenge and opportunity to uncover novel 
therapeutic targets for ILC based on pathways that are specifically activated. However, one 
caveat that requires further study is understanding the efficacy of IGF1R inhibition in ILC 
tumors harboring mutations in PIK3CA or PTEN downstream of IGF1R that result in hyperactive 
Akt activity—these alterations are quite frequent in this subtype of breast cancer (61%)15. 
Therefore, we investigated the combination of a small molecule PI3K/mTOR inhibitor with 
endocrine therapy in ER+ ILC cells, and also observed a synergistic inhibition of cell viability. 
This approach may potentially serve as an alternative to targeted IGF1R therapy in tumors 
harboring PIK3CA/PTEN alterations to inhibit this mutation-induced pathway activation more 
directly.  There may also be a benefit in combining PI3K targeted therapy in combination with 
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anti-IGF1R therapy in tumors harboring PIK3CA mutations. Recent data from Cantley and 
colleagues suggest that elevated levels of insulin may provide a mechanism of resistance to 
tumors harboring PIK3CA that are treated with PI3K targeted therapy158. Because the insulin and 
IGF1 signaling pathways are highly homologous, it is possible that IGF1 plays a similar role as a 
resistance mechanism. Future studies will serve to elucidate these interactions using in vivo and 
ex vivo drug screening to assess the combinations of IGF1R, PI3K, mTOR, and ER targeted 
therapy in ILC tumors of various genetic backgrounds (e.g. PIK3CA mutant, PTEN null, wild-
type). 
Overall, our data suggest that the loss of E-cadherin may be used a biomarker for IGF1R 
activity and therefore, a predictor for response to anti-IGF1R therapy. The loss of E-cadherin in 
ILC is genetic, however, other tumor types, such triple negative breast cancers that have 
undergone EMT, have an epigenetic and/or transcriptional downregulation of E-cadherin—and 
similar to data published by our lab, the basal and mesenchymal subtypes of TNBC are thought 
to be in part driven by IGF1-IGF1R signaling87,112,168. We hypothesize these tumors may also be 
susceptible to anti-IGF1R therapy. We will test this in future studies with similar methodology as 
described for ILC tumors, however, combining IGF1R pathway inhibitors with standard of care 
chemotherapy in TNBC with low E-cadherin expression. In addition, a number of studies have 
previously investigated and provided evidence for predictive biomarkers for IGF1R targeted 
therapy—including increased levels of circulating IGF1, and expression of IGF1R, IRS1/2, and 
IGFBP3107,109,169,170. The results from these studies highlight the importance of determining 
whether the IGF1-IGF1R pathway is active when treating with anti-IGF1R therapy and 
therefore, these factors would also need to be assessed in tumors with loss of E-cadherin to 
ensure the treatment would be useful.  In conclusion, the data presented in this dissertation 
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indicate that the loss of E-cadherin induces IGF1R pathway hyperactivation, and therefore, E-




Figure 20: Schematic for IGF1R/E-cadherin bi-directional signaling repression in normal mammary 
gland and dysregulation in ILC tumors. 
A simplified schematic depicting the bi-directional repression of E-cadherin and IGF1R in the normal 
mammary gland and the loss of repression in ILC tumors. A similar repression likely occurs in TNBC with 
low E-cadherin levels via epigenetic or transcriptional repression, rather than genetic loss as in ILC. 
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APPENDIX A 
EVALUATING THE ACTIVITY OF THE GH-GHR AXIS IN BREAST CANCER 
A.1 INTRODUCTION 
Growth hormone (GH)-mediated signaling begins at an endocrine level with growth hormone 
releasing hormone secretion from the hypothalamus, which subsequently induces the release of 
GH from the anterior pituitary gland. GH stimulates production of insulin-like growth factor-1 
(IGF1) by the liver to regulate normal growth171. GH binds the homodimerized growth hormone 
receptor (GHR), a membrane spanning receptor belonging to the cytokine Type I receptor 
family, to induce a conformational change that allows for the phosphorylation of the tyrosine 
kinases JAK2 and c-SRC. This leads to activation of downstream signaling through the 
JAK/STAT and PI3K/Akt pathways172,173. 
The GH/IGF1 axis is a major regulator of body growth and longevity, likely in part due 
to its regulation of multiple stem cell lineages29,171,174,175. Deregulation of the GH/IGF1 axis has 
been implicated in breast cancer, in part by contributing to the proliferation and expansion of 
cancer stem cells174,176. Strikingly, spontaneous dwarf rats that lack GH are completely refractory 
to carcinogen-induced mammary cancer, and supplementation with GH restores tumor 
development177,178. Similarly, by blocking GHR function with the antagonist, pegvisomant (FDA 
approved for the treatment of acromegaly), we demonstrated effective growth inhibition of 
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MCF-7 xenograft tumors179. Conversely, overexpression of GH transforms mammary epithelial 
cells and increases proliferation of breast cancer cells180–182.  
While GH acts in an endocrine manner, it is also secreted locally by breast cancer cells in 
an autocrine and paracrine fashion, promoting proliferation, migration and invasion, epithelial to 
mesenchymal transition, expansion of the progenitor population, and resistance to radiation 
therapy176,181–185. Lombardi and colleagues showed that GH regulates mammary stem cell 
number and function, and that GH is increased in early breast premalignant lesions176. It is 
possible that GH is a critical regulator of cancer stem cells or tumor initiating cells driving tumor 
formation or recurrence following treatment176,184. We hypothesize that breast tumors may have a 
population of cells with hyperactivity of the GH-GHR signaling pathway and therefore, may be 
effectively targeted by inhibiting GHR action.  
A.2 MATERIALS AND METHODS 
A.2.1 Cell culture 
All cell lines were acquired from ATCC and cultured in the indicated media conditions: T47D 
(RPMI+10% FBS), MDA-MB-453 (MM453; DMEM+10% FBS), MDA-MB-415 (MM415; 
DMEM+10% FBS), HCC1806 (RPMI+10% FBS), HCC1954 (RPMI+10% FBS), BT549 
(RPMI+10% FBS), and MCF10A (DMEM/F12+5% horse serum supplemented with 10ug/ml 
insulin, 20ng/ml EGF, 0.1ug/ml cholera toxin, and 2.5ug/ml hydrocortisone). 
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A.2.2 Growth factor (hGH/IGF1) stimulation and treatment with GHR blocking antibody 
T47D cells were plated and then serum-starved overnight. As indicated, cells were stimulated 
with vehicle (10mM HCl), 100ng/ml or 1ug/ml human growth hormone (hGH; Sigma #H5916) 
and 50ng/ml IGF1 (GroPep BioReagents #CU100) to assess signaling (45 min) or viability (6 or 
8 days). For signaling experiments assessing the effect of GHR blocking antibody, serum-starved 
T47D cells were treated with 100ng/ml hGH in combination with 1ug/ml GHR blocking 
antibody (R&D Systems #AF1210) for 1 or 4 hours. 
A.2.3 Immunoblotting 
Samples for immunoblot analysis were collected using RIPA buffer (50mM Tris pH 7.4, 150mM 
NaCl, 1mM EDTA, 0.5% Nonidet P-40, 0.5% NaDeoxycholate, 0.1% SDS) supplemented with 
1x HALT protease and phosphatase cocktail (Thermo Fisher #78442), probe sonicated for 15 
seconds (20% amplitude), and centrifuged at 14,000rpm at 4˚C for 12 minutes. Protein 
concentration was assessed using BCA assay (Thermo Fisher #23225) and 50ug of protein per 
sample was run on 12% SDS-PAGE gel then transferred to PVDF membrane. Membranes were 
blocked for 1 hour using Odyssey PBS Blocking Buffer (LiCor #927-40000) then probed using 
the following primary antibodies and concentrations: GHR (EMD Millipore #ABC444; 1:500), 
pSTAT5 (Y694, Cell Signaling #9350; 1:500), pSTAT3 (Y705, Cell Signaling #9145; 1:500), 
STAT5A/B (Cell Signaling #9363; 1:500), STAT3 (Cell Signaling #4904; 1:500), and β-actin 
(Sigma #A5441; 1:5000). Membranes were then washed in TBST, incubated in LiCor secondary 
antibody (1:10,000) for 1 hour (anti-rabbit 800CW [LiCor #926-32211]; anti-mouse 680LT 
[LiCor #925-68020]), then imaged using the Odyssey Infrared Imager. 
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A.2.4 Transient siRNA knockdown 
Cells were reverse transfected into 96-well (2D adherent) plates with 50nM final concentration 
of ON-TARGETplus non-targeting control pool siRNA (Dharmacon #D-001810) or ON-
TARGETplus human GHR siRNA (Dharmacon #L-010402) using standard Lipofectamine 
RNAiMAX (Invitrogen #13778) protocol.  
A.2.5 Viability assays 
Following reverse transfection of SCR or GHR siRNA in 2D 96-well plates, cell viability was 
assessed on day 6 using the FluoReporter Blue Fluorometric DNA Quantitation Kit (Thermo 
Fisher #F2962) following the manufacturer’s protocol. Statistical difference in Hoechst 
fluorescence in siSCR compared to siGHR cells in each cell line was evaluated using a two-
tailed student’s t-test (p<0.05). Following growth factor stimulation (hGH/IGF1) in ultra-low 
attachment suspension (ULA) 96-well plates, viability was assessed on days 6 and 8 using 
CellTiter Glo Viability assay (Promega #G7572) according to the manufacturer’s protocol. 
Statistical difference in relative luminescence in experimental growth conditions on days 6 and 8 
was evaluated using two-way ANOVA and Tukey’s multiple comparison test (p<0.05).  
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A.3 RESULTS 
A.3.1 Expression level of GHR varies in breast cancer cell lines and predicts response to 
GHR knockdown 
To assess the levels of GHR expression in breast cancer, we probed a panel of cell lines (T47D, 
MM453, MM415, MCF10A, HCC1806, HCC1954, BT549) for GHR protein expression by 
immunoblot. The highest GHR expression was observed in MCF10A (normal mammary 
epithelial cell line) and HCC1954 cells, and the lowest expression in HCC1806 and BT549 cells. 
T47D, MM453, and MM415 cells expressed an intermediate level of GHR compared to the high 
and low expressing cell lines (Figure 21).  
 
 
Figure 21: Growth hormone receptor (GHR) expression is variable among breast cancer cell lines. 
A panel of breast cancer cell lines ((T47D, MM453, MM415, MCF10A, HCC1806, HCC1954, BT549) was 
assessed by immunoblot for GHR expression. 
 
 
Then, we silenced GHR in these cell lines using siRNA and assessed the effect on cell viability 
to determine if the level of GHR expression is predictive of response to GHR knockdown. There 
was significantly decreased viability in MCF10A (p<0.0001), T47D (p<0.0001), HCC1954 
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(p=0.0007), and MM415 (p=0.0404) cells (high to intermediate basal expression of GHR) 




Figure 22: A subset of breast cancer cell lines are growth inhibited by GHR knockdown. 
(A) MCF10A, (B) T47D, (C) HCC1954, and (D) MM415 cell lines were reverse transfected with control 
(siSCR) and GHR (siGHR) siRNA for 6 days. Viability was assed using FluoReporter Blue Fluorometric 
DNA Quantitation Kit following the manufacturer’s protocol to measure DNA content. Statistical difference 
in Hoechst fluorescence in siSCR compared to siGHR cells in each cell line was evaluated using a two-tailed 
student’s t-test (p<0.05*, p<0.005***, p<0.001****). 
 
 
Conversely, there was no difference in viability between siGHR and siSCR cells in the MM453, 
HCC1806, and BT549 cell lines (low to intermediate basal expression of GHR [Figure 23A-C]). 
Knockdown was verified by qRT-PCR (data not shown). These results indicate that the protein 
expression level of GHR in breast cancer cells may be useful in predicting sensitivity to GHR 
knockdown or inhibition. 
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Figure 23: A subset of breast cancer cell lines are resistant to GHR knockdown. 
(A) MM453, (B) HCC1806, and (C) BT549 cell lines were reverse transfected with control (siSCR) and 
GHR (siGHR) siRNA for 6 days. Viability was assed using FluoReporter Blue Fluorometric DNA 
Quantitation Kit following the manufacturer’s protocol to measure DNA content. Statistical difference in 
Hoechst fluorescence in siSCR compared to siGHR cells in each cell line was evaluated using a two-tailed 
student’s t-test (p<0.05). No significant difference was detected between siSCR and siGHR in these cell lines. 
 
 
A.3.2 Growth hormone stimulation induces STAT3/5 activation that cannot be blocked by 
treatment with GHR blocking antibody 
To understand signaling downstream of GHR and its effects on cell proliferation, we stimulated 
T47D cells with human growth hormone (hGH). T47D cells are known to be highly hGH 
responsive, supported by our data that knockdown of GHR reduces cell viability (Figure 
22)186,187. Following serum-starvation, T47D cells were stimulated with 100ng/ml or 1ug/ml 
doses of hGH and phosphorylation of STAT5 and STAT3 was observed (Figure 24A). 
Interestingly, similar to previously published data, treatment with a GHR blocking antibody was 
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unable to inhibit hGH-induced STAT5 activation (Figure 24B)186. We then evaluated the effect 
of hGH stimulation on growth of T47D cells. Additionally, we combined hGH and IGF1 
stimulation to determine if there was an additive effect on growth, since these growth factors are 
in the same signaling family. Following serum-starvation and growth factor simulation, we 
observed statistically significant increases in viability in cells stimulated with both hGH and 






Figure 24: Growth hormone (hGH) stimulation induces JAK-STAT signaling and enhances viability 
of T47D cells. 
(A) T47D cells were serum-starved overnight and stimulated with 100 or 1000ng/ml hGH for 45 minutes or 
(B) stimulated with 100ng/ml hGH -/+ 1ug/ml GHR neutralizing antibody for 1 or 4 hours. JAK-STAT 
signaling (pSTAT5 (Y694)/pSTAT3 (Y705)) was assessed by immunoblot. (C) T47D cells were serum-
starved and plated into 96-well ULA plates and stimulated with either vehicle, 100ng/ml hGH, or hGH + 
50ng/ml IGF1. Viability was assessed on days 6 and 8 using CellTiter Glo Viability assay. Statistical 
difference in RLU in growth conditions on days 6 and 8 was evaluated using two-way ANOVA and Tukey’s 
multiple comparison test (p<0.05, p<0.0001****) 
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A.4 DISCUSSION 
In addition to the role of endocrine GH in regulating normal body growth and longevity, 
autocrine GH via GHR has been implicated as a potential driver for breast cancer. We sought to 
understand the effect of GHR knockdown on breast cancer cell viability and determine whether 
GHR protein expression serves as a biomarker for response to knockdown. Our data indicate that 
the breast cancer cell lines with higher expression of GHR (e.g. HCC1954, MM415) showed 
greater inhibition in cell viability following GHR silencing as compared to the lower expressing 
cell lines (e.g. HCC1806, BT549). However, T47D cells were significantly growth inhibited by 
GHR knockdown despite their intermediate expression of GHR. Of note, MCF10A, an 
immortalized non-transformed mammary epithelial cell line, demonstrated high expression of 
GHR and significant sensitivity to GHR siRNA knockdown indicating that this may not be a 
cancer cell specific effect. 
 Because T47D cells were sensitive to GHR knockdown, and known to be hGH 
responsive, we stimulated these cells with hGH to determine effect on downstream signaling and 
cell viability. As expected, stimulation with hGH activated the STAT5 and STAT3 signaling 
pathways, and induced increased viability in serum-starved cells compared to control cells. 
Interestingly though, treatment with a GHR neutralizing antibody was unable to block STAT5 
activation by hGH, similar to results published by Xu and colleagues186. Additionally, the 
authors showed heterodimerization of GHR and prolactin receptor (PRLR) in T47D cells, and 
further demonstrated that hGH preferentially activates PRLR to initiate downstream signaling 
through the JAK-STAT pathway (a pathway shared by both GHR and PRLR). Therefore, further 
studies are necessary to assess whether the growth induction observed in our experiment is due 
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to JAK-STAT signaling mainly via PRLR activation, or whether additional signaling pathways 























CHAPTER 3 SUPPLEMENTARY FIGURES 
 
 
Figure 25: Knockdown of E-cadherin enhances IGF1-induced proliferation. 
T47D shSCR and two clones of shCDH1 cells were plated in 96 well plates (9,000 cells per well) in serum-
free media. Cells were treated with Vhc or 10nM IGF1 for 6 days and dsDNA content measured. Statistical 
difference in Hoechst fluorescence in IGF1 treated cells over vehicle control in each cell line was evaluated 
using a two-tailed student’s t-test (p<0.05). One representative experiment shown; n=2 each with 6 biological 
replicates. Of note each shCDH1 clone displayed statistically significant increase in viability compared to 








Figure 26: Overexpression of E-cadherin in MDA-MB-231 cells inhibits IGF1R mediated signaling, 
despite the lack of adherens junction formation. 
(A-B) MDA-MB-231 (MM231) cells lacking detectable E-cadherin protein expression were stably 
transfected with empty of hE-cadherin-pcDNA3 vector. Cells were stimulated with Vhc or 10nM IGF1 for 
10 min and IGF1R and Akt signaling assessed by immunoblot (shown in duplicate biological replicates). (C) 
Cells were serum-starved and stimulated with 10nM IGF1 for 17 hours and DNA stained with propidium 
iodide to measure cell cycle profile. The percent of cells in the IGF1/Vhc conditions in the S- and G2/M 































Figure 27: Knockdown of E-cadherin increases sensitivity to IGF1R inhibition in ZR75.1 cells grown 
in ULA. 
ZR75.1 cells were reverse transfected with SCR or CDH1 siRNA and seeded into 96-well 2D or ULA plates 
and treated with IGF1R inhibitor (OSI-906 or BMS-754807) for 6 days. Conditions in the panels as follows: 
(A) OSI-906; 2D, (B) OSI-906; ULA, (C) BMS-754807; 2D, (D) BMS-754807; ULA. The CellTiter Glo 
assay was used to assess cell viability (relative luminescence). EC50 values for viability were calculated by 
non-linear regression and statistical differences evaluated using sum-of-squares Global f-test (p<0.05; 





















Figure 28: Loss of E-cadherin increases sensitivity to IGF1R inhibition in T47D cells grown in ULA. 
T47D cells were reverse transfected with SCR or CDH1 siRNA and seeded into 96-well 2D or ULA plates 
and treated with IGF1R inhibitor (OSI-906 or BMS-754807) for 6 days. Conditions in the panels as follows: 
(A) OSI-906; 2D, (B) OSI-906; ULA, (C) BMS-754807; 2D, (D) BMS-754807; ULA. The CellTiter Glo 
assay was used to assess cell viability (relative luminescence). EC50 values for viability were calculated by 
non-linear regression and statistical differences evaluated using sum-of-squares Global f-test (p<0.05; 




















Figure 29: Loss of E-cadherin does not alter sensitivity to ICI 182,780 in breast cancer cells. 
MCF-7 cells were reverse transfected with SCR or CDH1 siRNA and seeded into 96-well (A) 2D or (B) ULA 
plates and treated with ICI 182,780 for 6 days. CellTiter Glo assay was used to assess cell viability (relative 
luminescence). EC50 values for viability were calculated by non-linear regression and statistical differences 























Figure 30: IGF1R and E-cadherin primary antibodies and Duolink secondary antibody probes are 
specific for the IGF1R-E-cadherin interaction. 
MCF-7 cells were reverse transfected with SCR, CDH1, or IGF1R siRNA for 48 hours and plated on 
coverslips. (A) siSCR, (B) siCDH1, and (C) siIGF1R cells were fixed and immunostained for IGF1R 
(green) and E-cadherin (red) overnight, then imaged using confocal microscopy to demonstrate knockdown 
efficiency. MCF-7 cells were plated on coverslips, fixed, and stained with either (D) E-cadherin antibody 
alone, (E) IGF1R antibody alone, or (F) no primary antibody overnight. The Duolink (Sigma) protocol was 
followed and coverslips were imaged using confocal microscopy to assess non-specific interaction of 
Duolink secondary antibody probes. 
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CHAPTER 4 SUPPLEMENTARY FIGURES/TABLES 
 
 
Figure 31: ILC cell lines are highly IGF1 responsive. 
MM134, MM330, SUM44PE and BCK4 ILC (red) and MCF-7 (blue) cell lines were plated in 6-well plates 
at no more than 70% confluency. Cells were serum-starved overnight and then stimulated with IGF1 
(10nM) for 10 minutes. IGF1R activation was assessed by immunoblot as measured by phosphorylation of 
IGF1R (pIGF1R). Of note, MM330 cells express E-cadherin protein, but harbor a mutation in α-catenin 

















Figure 32: IGF1R pathway inhibitors and endocrine therapy synergize to inhibit cell viability in 
MDA-MB-134 ILC cells. 
MM134 ILC cells were plated into 96-well ULA plates and treated for 6 days with increasing doses of (A, 
B) OSI-906, (C, D) BMS-754807, or (E, F) BEZ235 in combination with increasing doses of ICI 182,780. 
The dose response curves and heat maps shown indicate inhibition of cell viability (relative luminescence 
as measured by CellTiter Glo). Representative experiment shown; n=3 independent experiments each with 






Table 3: Combination index values indicating a synergist relationship between IGF1R pathway 
inhibitors and ICI 182, 780 to inhibit cell viability. 
Synergy was measured using the Median-Effect Principle and Combination-Index Isoblogram Theorem. 
The table displays the E50, ED75, and ED90 values from inhibitors OSI-906, BMS-754807, or BEZ235 in 
combination with ICI 182,780. Values are shown +/- SEM from 3 independent experiments each with n=2 




























Figure 33: PI3K/mTOR inhibition reduces proliferation in an ILC tumor harboring PIK3CA 
mutation in ex vivo culture. 
WHIM9 patient-derived xenograft tumor was harvested from immunocompromised mice, minced into 1-
2mm3 tumor chunks and then plated on gelatin sponges in 12-well plate containing 1.5ml media. Media was 
treated with (A) DMSO Vhc, (B) 1uM BMS-75807, or (C) 100nM BEZ235 for 72 hours. Tumor pieces were 
harvested by FFPE and stained for Ki67 as a marker of proliferation. (D) Staining was quantified by counting 
all clearly defined nuclei in 20x images. Statistical difference was assessed using a Student’s t-test (p<0.05; 
n=7-8). Ki67 staining quantification was completed by Justin Kehm and Kara Burlbaugh (undergraduates; 
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